BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548-4554. [PMID: 21969517 DOI: 10.1200/jco.2011.36.5742] [Cited by in Crossref: 692] [Cited by in F6Publishing: 712] [Article Influence: 62.9] [Reference Citation Analysis]
Number Citing Articles
1 Li ZH, Ma YJ, Jia ZH, Weng YY, Zhang P, Zhu SJ, Wang F. Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer. World J Clin Cases 2022; 10(27): 9703-9713 [DOI: 10.12998/wjcc.v10.i27.9703] [Reference Citation Analysis]
2 Zhang H, Dong H, Pan Z, Du X, Liu S, Xu W, Zhang Y. Risk factors and predictive nomograms for early death of patients with pancreatic cancer liver metastasis: A large cohort study based on the SEER database and Chinese population. Front Oncol 2022;12:998445. [DOI: 10.3389/fonc.2022.998445] [Reference Citation Analysis]
3 He F, Zhou X, Huang G, Jiang Q, Wan L, Qiu J, Yuchi A. Establishment and Identification of Patient-Derived Xenograft Model for Oral Squamous Cell Carcinoma. Journal of Oncology 2022;2022:1-7. [DOI: 10.1155/2022/3135470] [Reference Citation Analysis]
4 Kachmazov A, Bolotina L, Kornietskaya A, Kuznetsova O, Ivanov M, Fedenko A. Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review. Front Oncol 2022;12:953908. [DOI: 10.3389/fonc.2022.953908] [Reference Citation Analysis]
5 Cele N, Awolade P, Dhawan S, Khubone L, Raza A, Sharma AK, Singh P. Quinoline–1,3,4-Oxadiazole Conjugates: Synthesis, Anticancer Evaluation, and Molecular Modelling Studies. Polycyclic Aromatic Compounds. [DOI: 10.1080/10406638.2022.2117205] [Reference Citation Analysis]
6 Alshememry AK, Alsaleh NB, Alkhudair N, Alzhrani R, Alshamsan A. Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview. Front Pharmacol 2022;13:933457. [DOI: 10.3389/fphar.2022.933457] [Reference Citation Analysis]
7 Ohba A, Ueno H, Shiba S, Okano N, Kobayashi T, Nagashima F, Sasahira N, Sasaki M, Imaoka H, Sakamoto Y, Kondo S, Morizane C, Ozaka M, Ikeda M, Furuse J, Okusaka T. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial. Eur J Cancer 2022;174:40-7. [PMID: 35970035 DOI: 10.1016/j.ejca.2022.06.010] [Reference Citation Analysis]
8 Heger U, Martens A, Schillings L, Walter B, Hartmann D, Hinz U, Pausch T, Giese N, Michalski CW, Hackert T. Myofibroblastic CAF Density, Not Activated Stroma Index, Indicates Prognosis after Neoadjuvant Therapy of Pancreatic Carcinoma. Cancers 2022;14:3881. [DOI: 10.3390/cancers14163881] [Reference Citation Analysis]
9 Okano N, Matsuki R, Toki M, Gondo K, Ochiai K, Watanabe S, Tateishi H, Kogure M, Suzuki Y, Sugiyama M, Nagashima F, Shibahara J, Sakamoto Y, Furuse J. A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer. Intern Med 2022. [PMID: 35793961 DOI: 10.2169/internalmedicine.9504-22] [Reference Citation Analysis]
10 Fuller AM, Eisinger-mathason TSK. Context Matters: Response Heterogeneity to Collagen-Targeting Approaches in Desmoplastic Cancers. Cancers 2022;14:3132. [DOI: 10.3390/cancers14133132] [Reference Citation Analysis]
11 Lv S, Lin M, Yang Z, Xu C, Wu Z. Survival Analysis and Prediction Model of ASCP Based on SEER Database. Front Oncol 2022;12:909257. [DOI: 10.3389/fonc.2022.909257] [Reference Citation Analysis]
12 Götze J, Nitschke C, Uzunoglu FG, Pantel K, Sinn M, Wikman H. Tumor-Stroma Interaction in PDAC as a New Approach for Liquid Biopsy and its Potential Clinical Implications. Front Cell Dev Biol 2022;10:918795. [PMID: 35712663 DOI: 10.3389/fcell.2022.918795] [Reference Citation Analysis]
13 Cole KE, Ly QP, Hollingsworth MA, Cox JL, Fisher KW, Padussis JC, Foster JM, Vargas LM, Talmadge JE. Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients. International Immunopharmacology 2022;106:108628. [DOI: 10.1016/j.intimp.2022.108628] [Reference Citation Analysis]
14 Kato A, Naitoh I, Naiki-Ito A, Hayashi K, Okumura F, Fujita Y, Sano H, Nishi Y, Miyabe K, Inoue T, Hirano A, Takada H, Yoshida M, Hori Y, Natsume M, Kato H, Takahashi S, Kataoka H. Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer. Pancreas 2022;51:372-9. [PMID: 35695793 DOI: 10.1097/MPA.0000000000002032] [Reference Citation Analysis]
15 Pijnappel EN, Schuurman M, Wagner AD, de Vos-geelen J, Geest LGMVD, de Groot JB, Koerkamp BG, de Hingh IHJT, Homs MYV, Creemers G, Cirkel GA, van Santvoort HC, Busch OR, Besselink MG, van Eijck CH, Wilmink JW, van Laarhoven HWM. Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study. Front Oncol 2022;12:839779. [DOI: 10.3389/fonc.2022.839779] [Reference Citation Analysis]
16 Selvanesan BC, Chandra D, Quispe-Tintaya W, Jahangir A, Patel A, Meena K, Alves Da Silva RA, Friedman M, Gabor L, Khouri O, Libutti SK, Yuan Z, Li J, Siddiqui S, Beck A, Tesfa L, Koba W, Chuy J, McAuliffe JC, Jafari R, Entenberg D, Wang Y, Condeelis J, DesMarais V, Balachandran V, Zhang X, Lin K, Gravekamp C. Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice. Sci Transl Med 2022;14:eabc1600. [PMID: 35320003 DOI: 10.1126/scitranslmed.abc1600] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
17 Ciunci C, Reibel J, Evans T, Mick R, Bauml J, Aggarwal C, Marmarelis M, Singh A, D'avella C, Cohen R, Langer C. Phase II trial of combination nab-paclitaxel and gemcitabine in non-squamous non-small cell lung cancer after progression on platinum and pemetrexed. Clinical Lung Cancer 2022. [DOI: 10.1016/j.cllc.2022.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhu X, Cao Y, Liu W, Ju X, Zhao X, Jiang L, Ye Y, Jin G, Zhang H. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial. The Lancet Oncology 2022;23:e105-15. [DOI: 10.1016/s1470-2045(22)00066-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Jing Y, Liang W, Zhang L, Tang J, Huang Z. The Role of Mesenchymal Stem Cells in the Induction of Cancer-Stem Cell Phenotype. Front Oncol 2022;12:817971. [DOI: 10.3389/fonc.2022.817971] [Reference Citation Analysis]
20 Liu L, Huang X, Shi F, Song J, Guo C, Yang J, Liang T, Bai X. Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. J Exp Clin Cancer Res 2022;41:56. [PMID: 35139879 DOI: 10.1186/s13046-022-02273-w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Qu C, Zeng P, Wang H, Yuan C, Yuan H, Xiu D. Application of Magnetic Resonance Imaging in Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma. Magnetic Resonance Imaging. [DOI: 10.1002/jmri.28096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Halwani AA. Development of Pharmaceutical Nanomedicines: From the Bench to the Market. Pharmaceutics 2022;14:106. [PMID: 35057002 DOI: 10.3390/pharmaceutics14010106] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 18.0] [Reference Citation Analysis]
23 Xu X, Wu Y, Qian X, Wang Y, Wang J, Li J, Li Y, Zhang Z. Nanomedicine Strategies to Circumvent Intratumor Extracellular Matrix Barriers for Cancer Therapy. Adv Healthc Mater 2022;11:e2101428. [PMID: 34706400 DOI: 10.1002/adhm.202101428] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Meneses-medina MI, Gervaso L, Cella CA, Pellicori S, Gandini S, Sousa MJ, Fazio N. Chemotherapy in pancreatic ductal adenocarcinoma: when cytoreduction is the aim. A systematic review and meta-analysis. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102338] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Winter K, Dzieniecka M, Strzelczyk J, Wągrowska-Danilewicz M, Danilewicz M, Małecka-Wojciesko E. Alpha Smooth Muscle Actin (αSMA) Immunohistochemistry Use in the Differentiation of Pancreatic Cancer from Chronic Pancreatitis. J Clin Med 2021;10:5804. [PMID: 34945100 DOI: 10.3390/jcm10245804] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Zhang Z, Zhang HJ. Glycometabolic rearrangements-aerobic glycolysis in pancreatic ductal adenocarcinoma (PDAC): roles, regulatory networks, and therapeutic potential. Expert Opin Ther Targets 2021;:1-17. [PMID: 34874212 DOI: 10.1080/14728222.2021.2015321] [Reference Citation Analysis]
27 Huang S, Huang X, Yan H. Peptide dendrimers as potentiators of conventional chemotherapy in the treatment of pancreatic cancer in a mouse model. Eur J Pharm Biopharm 2021:S0939-6411(21)00278-2. [PMID: 34801706 DOI: 10.1016/j.ejpb.2021.11.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Huang X, Li M, Hou S, Tian B. Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review). Int J Oncol 2021;59:101. [PMID: 34738624 DOI: 10.3892/ijo.2021.5281] [Reference Citation Analysis]
29 Liu T, Li Q, Zhang W, Zhu Q. Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review. Front Oncol 2021;11:733955. [PMID: 34676166 DOI: 10.3389/fonc.2021.733955] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Schizas D, Koumpoura A, Galari M, Economopoulou P, Vailas M, Sotiropoulou M, Dimitroulis D, Maroulis I, Felekouras E. A personalized approach to pancreatic ductal adenocarcinoma and its application in surgical practice. Per Med 2021;18:613-27. [PMID: 34676789 DOI: 10.2217/pme-2021-0031] [Reference Citation Analysis]
31 Malchiodi ZX, Cao H, Gay MD, Safronenka A, Bansal S, Tucker RD, Weinberg BA, Cheema A, Shivapurkar N, Smith JP. Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment. Cancers (Basel) 2021;13:4949. [PMID: 34638432 DOI: 10.3390/cancers13194949] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Pijnappel EN, Wassenaar NPM, Gurney-Champion OJ, Klaassen R, van der Lee K, Pleunis-van Empel MCH, Richel DJ, Legdeur MC, Nederveen AJ, van Laarhoven HWM, Wilmink JW. Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer. Cancers (Basel) 2021;13:4869. [PMID: 34638351 DOI: 10.3390/cancers13194869] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Zhang Z, Pu J, Zhang H. Development and Validation of a Simple-to-Use Nomogram to Predict Early Death in Metastatic Pancreatic Adenocarcinoma. Front Oncol 2021;11:729175. [PMID: 34568061 DOI: 10.3389/fonc.2021.729175] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
34 Cho IK, Kim H, Lee JC, Lee J, Kim J, Ahn S, Park H, Hwang JH. Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator. Gut Liver 2020;14:521-8. [PMID: 31615191 DOI: 10.5009/gnl19180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Wang X, Hu L, Yang X, Chen F, Xu H, Yu H, Song Z, Fei J, Zhong Z. Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy. Exp Ther Med 2021;22:1140. [PMID: 34504586 DOI: 10.3892/etm.2021.10574] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Michl P, Löhr M, Neoptolemos JP, Capurso G, Rebours V, Malats N, Ollivier M, Ricciardiello L. UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. United European Gastroenterol J 2021. [PMID: 34431604 DOI: 10.1002/ueg2.12123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
37 He B, Sui X, Yu B, Wang S, Shen Y, Cong H. Recent advances in drug delivery systems for enhancing drug penetration into tumors. Drug Deliv 2020;27:1474-90. [PMID: 33100061 DOI: 10.1080/10717544.2020.1831106] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
38 Edwards P, Kang BW, Chau I. Targeting the Stroma in the Management of Pancreatic Cancer. Front Oncol 2021;11:691185. [PMID: 34336679 DOI: 10.3389/fonc.2021.691185] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
39 Liu X, Wu W, Cui D, Chen X, Li W. Functional Micro-/Nanomaterials for Multiplexed Biodetection. Adv Mater 2021;33:e2004734. [PMID: 34137090 DOI: 10.1002/adma.202004734] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
40 Xelwa N, Candy GP, Devar J, Omoshoro-Jones J, Smith M, Nweke EE. Targeting Growth Factor Signaling Pathways in Pancreatic Cancer: Towards Inhibiting Chemoresistance. Front Oncol 2021;11:683788. [PMID: 34195085 DOI: 10.3389/fonc.2021.683788] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Zhu X, Liu W, Cao Y, Su T, Zhu X, Wang Y, Ju X, Zhao X, Jiang L, Ye Y, Zhang H. Development and Validation of Multicenter Predictive Nomograms for Locally Advanced Pancreatic Cancer After Chemoradiotherapy. Front Oncol 2021;11:688576. [PMID: 34169000 DOI: 10.3389/fonc.2021.688576] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Cui J, Yang H, Liu J, Chen D, Hu J, Zhang H, Wang Y, Han T, Mao T, Jiao F, Biskup E, Pan Y, Liu M, Wang L. A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer 2021;21:672. [PMID: 34098895 DOI: 10.1186/s12885-021-08375-6] [Reference Citation Analysis]
43 Hani U, Osmani RAM, Siddiqua A, Wahab S, Batool S, Ather H, Sheraba N, Alqahtani A. A systematic study of novel drug delivery mechanisms and treatment strategies for pancreatic cancer. Journal of Drug Delivery Science and Technology 2021;63:102539. [DOI: 10.1016/j.jddst.2021.102539] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
44 Manoharan D, Chang LC, Wang LC, Shan YS, Lin FC, Wu LC, Sheu HS, Su WP, Yeh CS. Synchronization of Nanoparticle Sensitization and Radiosensitizing Chemotherapy through Cell Cycle Arrest Achieving Ultralow X-ray Dose Delivery to Pancreatic Tumors. ACS Nano 2021;15:9084-100. [PMID: 33974409 DOI: 10.1021/acsnano.1c02283] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
45 Albahde MAH, Abdrakhimov B, Li GQ, Zhou X, Zhou D, Xu H, Qian H, Wang W. The Role of Microtubules in Pancreatic Cancer: Therapeutic Progress. Front Oncol 2021;11:640863. [PMID: 34094924 DOI: 10.3389/fonc.2021.640863] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
46 Chang C, Li X, Cao D. Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study. BMC Cancer 2021;21:545. [PMID: 33985455 DOI: 10.1186/s12885-021-08275-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Ahmad IM, Dafferner AJ, O'Connell KA, Mehla K, Britigan BE, Hollingsworth MA, Abdalla MY. Heme Oxygenase-1 Inhibition Potentiates the Effects of Nab-Paclitaxel-Gemcitabine and Modulates the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:2264. [PMID: 34066839 DOI: 10.3390/cancers13092264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
48 Huang X, Wang C, Ma T, Huang Z, Zhou H, Xu L, Zhang R, Zhao J, Zhang Y, Huang Z, Shao L, Wang Y, Yang F, Che X. The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case Report. Front Oncol 2021;11:585983. [PMID: 33996534 DOI: 10.3389/fonc.2021.585983] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Hu X, Xia F, Lee J, Li F, Lu X, Zhuo X, Nie G, Ling D. Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma. Adv Sci (Weinh) 2021;8:2002545. [PMID: 33854877 DOI: 10.1002/advs.202002545] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
50 Tentes AK. Hyperthermic intra-operative intraperitoneal chemotherapy as an adjuvant to pancreatic cancer resection. J Gastrointest Oncol 2021;12:S91-8. [PMID: 33968429 DOI: 10.21037/jgo-20-46] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
51 Golan T, Atias D, Stossel C, Raitses-Gurevich M. Patient-derived xenograft models of BRCA-associated pancreatic cancers. Adv Drug Deliv Rev 2021;171:257-65. [PMID: 33617901 DOI: 10.1016/j.addr.2021.02.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
52 Chang CY, Lin CC. Hydrogel Models with Stiffness Gradients for Interrogating Pancreatic Cancer Cell Fate. Bioengineering (Basel) 2021;8:37. [PMID: 33805737 DOI: 10.3390/bioengineering8030037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
53 Hurtado de Mendoza T, Mose ES, Botta GP, Braun GB, Kotamraju VR, French RP, Suzuki K, Miyamura N, Teesalu T, Ruoslahti E, Lowy AM, Sugahara KN. Tumor-penetrating therapy for β5 integrin-rich pancreas cancer. Nat Commun 2021;12:1541. [PMID: 33750829 DOI: 10.1038/s41467-021-21858-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
54 Botrus G, Kosirorek H, Sonbol MB, Kusne Y, Uson Junior PLS, Borad MJ, Ahn DH, Kasi PM, Drusbosky LM, Dada H, Surapaneni PK, Starr J, Ritter A, McMillan J, Wylie N, Mody K, Bekaii-Saab TS. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. Oncologist 2021;26:569-78. [PMID: 33555095 DOI: 10.1002/onco.13717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
55 Okada Y, Takahashi N, Takayama T, Goel A. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma. Carcinogenesis 2021;42:546-56. [PMID: 33624791 DOI: 10.1093/carcin/bgab011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
56 Okada Y, Nishiwada S, Yamamura K, Sho M, Baba H, Takayama T, Goel A. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma. Eur J Cancer 2021;146:125-34. [PMID: 33607476 DOI: 10.1016/j.ejca.2020.12.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Burrack AL, Rollins MR, Spartz EJ, Mesojednik TD, Schmiechen ZC, Raynor JF, Wang IX, Kedl RM, Stromnes IM. CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model. J Immunol 2021;206:1372-84. [PMID: 33558374 DOI: 10.4049/jimmunol.2000765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
58 Kim SI, Cassella CR, Byrne KT. Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. Front Immunol 2020;11:629722. [PMID: 33597954 DOI: 10.3389/fimmu.2020.629722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
59 Zhang X, Detering L, Sultan D, Luehmann H, Li L, Heo GS, Zhang X, Lou L, Grierson PM, Greco S, Ruzinova M, Laforest R, Dehdashti F, Lim KH, Liu Y. CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. ACS Nano 2021;15:1186-98. [PMID: 33406361 DOI: 10.1021/acsnano.0c08185] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
60 Han X, Ma L, Gu J, Wang D, Li J, Lou W, Saiyin H, Fu D. Basal microvilli define the metabolic capacity and lethal phenotype of pancreatic cancer. J Pathol 2021;253:304-14. [PMID: 33159698 DOI: 10.1002/path.5588] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Fusco MJ, Saeed-Vafa D, Carballido EM, Boyle TA, Malafa M, Blue KL, Teer JK, Walko CM, McLeod HL, Hicks JK, Extermann M, Fleming JB, Knepper TC, Kim DW. Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer. JCO Precis Oncol 2021;5:PO. [PMID: 34250383 DOI: 10.1200/PO.20.00265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
62 Gamradt P, De La Fouchardière C, Hennino A. Stromal Protein-Mediated Immune Regulation in Digestive Cancers. Cancers (Basel) 2021;13:E146. [PMID: 33466303 DOI: 10.3390/cancers13010146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
63 Reni M. APX005M, a CD40 monoclonal antibody, for patients with pancreatic adenocarcinoma. Lancet Oncol 2021;22:10-1. [PMID: 33387488 DOI: 10.1016/S1470-2045(20)30724-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Allen SD, Liu X, Jiang J, Liao YP, Chang CH, Nel AE, Meng H. Immune checkpoint inhibition in syngeneic mouse cancer models by a silicasome nanocarrier delivering a GSK3 inhibitor. Biomaterials 2021;269:120635. [PMID: 33422940 DOI: 10.1016/j.biomaterials.2020.120635] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
65 Zhu X, Cao Y, Su T, Zhu X, Ju X, Zhao X, Jiang L, Ye Y, Cao F, Qing S, Zhang H. Failure patterns and outcomes of dose escalation of stereotactic body radiotherapy for locally advanced pancreatic cancer: a multicenter cohort study. Ther Adv Med Oncol. 2020;12:1758835920977155. [PMID: 33403017 DOI: 10.1177/1758835920977155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
66 Zong Y, Peng Z, Wang X, Lu M, Shen L, Zhou J. Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma. Cancer Manag Res 2020;12:12657-66. [PMID: 33328763 DOI: 10.2147/CMAR.S263773] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Wang ZJ, Arif-Tiwari H, Zaheer A, Ameli S, Bhosale PR, Do RK, Goenka AH, Guimares AR, Sangster GP, Soloff EV, Tamm EP, Zins M, Kambadakone AR. Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional imaging techniques. Abdom Radiol (NY) 2020;45:4273-89. [PMID: 32936417 DOI: 10.1007/s00261-020-02723-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
68 Nie K, Zhang L, You Y, Li H, Guo X, Zhang Z, Zhang C, Ji Y. Irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma: a single-arm, three-centre, prospective study. Ther Adv Med Oncol 2020;12:1758835920970843. [PMID: 33240399 DOI: 10.1177/1758835920970843] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Lai Benjamin FL, Lu Rick X, Hu Y, Davenport HL, Dou W, Wang EY, Radulovich N, Tsao MS, Sun Y, Radisic M. Recapitulating pancreatic tumor microenvironment through synergistic use of patient organoids and organ-on-a-chip vasculature. Adv Funct Mater 2020;30:2000545. [PMID: 33692660 DOI: 10.1002/adfm.202000545] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
70 Iovanna J. Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer. Transl Oncol 2021;14:100965. [PMID: 33248412 DOI: 10.1016/j.tranon.2020.100965] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
71 Krishnamoorthy M, Lenehan JG, Burton JP, Maleki Vareki S. Immunomodulation in Pancreatic Cancer. Cancers (Basel) 2020;12:E3340. [PMID: 33198059 DOI: 10.3390/cancers12113340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
72 Selvanesan BC, Meena K, Beck A, Meheus L, Lara O, Rooman I, Gravekamp C. Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice. J Immunother Cancer 2020;8:e001250. [PMID: 33154149 DOI: 10.1136/jitc-2020-001250] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
73 Iede K, Yamada T, Kato R, Ueda M, Tsuda Y, Nakashima S, Ohta K, Matsuyama J, Ikenaga M, Tominaga S. Predictive implications of decreased CA19-9 at 8 weeks during nab-paclitaxel plus gemcitabine for the induction of second-line chemotherapy for patients with advanced pancreatic cancer. Cancer Rep (Hoboken) 2020;3:e1289. [PMID: 32969199 DOI: 10.1002/cnr2.1289] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Tian H, Lyu Y, Yang YG, Hu Z. Humanized Rodent Models for Cancer Research. Front Oncol 2020;10:1696. [PMID: 33042811 DOI: 10.3389/fonc.2020.01696] [Cited by in Crossref: 11] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
75 Kang S, Lee S, Park S. iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery. Polymers (Basel) 2020;12:E1906. [PMID: 32847045 DOI: 10.3390/polym12091906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
76 Hasanain A, Blanco BA, Yu J, Wolfgang CL. The importance of circulating and disseminated tumor cells in pancreatic cancer. Surg Open Sci 2019;1:49-55. [PMID: 32754693 DOI: 10.1016/j.sopen.2019.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Lumeau A, Cordelier P. One Two Punch: Combination Chemotherapy Knocks Out Pancreatic Cancer. Mol Ther 2020;28:1751-2. [PMID: 32702289 DOI: 10.1016/j.ymthe.2020.07.014] [Reference Citation Analysis]
78 Chen Y, Wang L, Luo S, Hu J, Huang X, Li PW, Zhang Y, Wu C, Tian BL. Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer. Drug Des Devel Ther 2020;14:2945-57. [PMID: 32801636 DOI: 10.2147/DDDT.S261017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Amano S, Kaino S, Shinoda S, Harima H, Matsumoto T, Fujisawa K, Takami T, Yamamoto N, Yamasaki T, Sakaida I. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. BMC Cancer 2020;20:681. [PMID: 32698792 DOI: 10.1186/s12885-020-07167-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
80 Sanità G, Armanetti P, Silvestri B, Carrese B, Calì G, Pota G, Pezzella A, d'Ischia M, Luciani G, Menichetti L, Lamberti A. Albumin-Modified Melanin-Silica Hybrid Nanoparticles Target Breast Cancer Cells via a SPARC-Dependent Mechanism. Front Bioeng Biotechnol 2020;8:765. [PMID: 32733871 DOI: 10.3389/fbioe.2020.00765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
81 Kakwere H, Ingham ES, Tumbale SK, Ferrara KW. Gemcitabine-retinoid prodrug loaded nanoparticles display in vitro antitumor efficacy towards drug-resilient human PANC-1 pancreatic cancer cells. Mater Sci Eng C Mater Biol Appl 2020;117:111251. [PMID: 32919625 DOI: 10.1016/j.msec.2020.111251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
82 Liu Z, Ahn MH, Kurokawa T, Ly A, Zhang G, Wang F, Yamada T, Sadagopan A, Cheng J, Ferrone CR, Liss AS, Honselmann KC, Wojtkiewicz GR, Ferrone S, Wang X. A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma. J Transl Med 2020;18:255. [PMID: 32580742 DOI: 10.1186/s12967-020-02414-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
83 Xiao X, Chen W, Wei ZW, Chu WW, Lu XF, Li B, Chen H, Meng SJ, Hao TF, Wei JT, He YL, Zhang CH. The Anti-Tumor Effect of Nab-Paclitaxel Proven by Patient-Derived Organoids. Onco Targets Ther 2020;13:6017-25. [PMID: 32612367 DOI: 10.2147/OTT.S237431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
84 Van de Sande L, Cosyns S, Willaert W, Ceelen W. Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review. Drug Deliv 2020;27:40-53. [PMID: 31858848 DOI: 10.1080/10717544.2019.1704945] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
85 Awad S, Alkashash AM, Amin M, Baker SJ, Rose JB. Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Front Oncol 2020;10:620. [PMID: 32477933 DOI: 10.3389/fonc.2020.00620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
86 Miller AL, Garcia PL, Yoon KJ. Developing effective combination therapy for pancreatic cancer: An overview. Pharmacol Res 2020;155:104740. [PMID: 32135247 DOI: 10.1016/j.phrs.2020.104740] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
87 Guo X, Xu Y, Ji Y, Fan Y, Wang D, Jin D, Zhuang R, Wu L, Lou W, Zhou Y. Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer. Journal of Pancreatology 2020;3:35-41. [DOI: 10.1097/jp9.0000000000000038] [Reference Citation Analysis]
88 Oba A, Ho F, Bao QR, Al-Musawi MH, Schulick RD, Del Chiaro M. Neoadjuvant Treatment in Pancreatic Cancer. Front Oncol. 2020;10:245. [PMID: 32185128 DOI: 10.3389/fonc.2020.00245] [Cited by in Crossref: 29] [Cited by in F6Publishing: 59] [Article Influence: 14.5] [Reference Citation Analysis]
89 Wu D, Li X, Zhang X, Han F, Lu X, Liu L, Zhang J, Dong M, Yang H, Li H. Pharmacometabolomics Identifies 3-Hydroxyadipic Acid, d-Galactose, Lysophosphatidylcholine (P-16:0), and Tetradecenoyl-l-Carnitine as Potential Predictive Indicators of Gemcitabine Efficacy in Pancreatic Cancer Patients. Front Oncol 2019;9:1524. [PMID: 32064236 DOI: 10.3389/fonc.2019.01524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
90 Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019;5:824-830. [PMID: 30998813 DOI: 10.1001/jamaoncol.2019.0270] [Cited by in Crossref: 105] [Cited by in F6Publishing: 164] [Article Influence: 52.5] [Reference Citation Analysis]
91 Karasic TB, O'Hara MH, Loaiza-Bonilla A, Reiss KA, Teitelbaum UR, Borazanci E, De Jesus-Acosta A, Redlinger C, Burrell JA, Laheru DA, Von Hoff DD, Amaravadi RK, Drebin JA, O'Dwyer PJ. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;5:993-998. [PMID: 31120501 DOI: 10.1001/jamaoncol.2019.0684] [Cited by in Crossref: 74] [Cited by in F6Publishing: 119] [Article Influence: 37.0] [Reference Citation Analysis]
92 Okada KI, Kawai M, Hirono S, Kojima F, Tanioka K, Terada M, Miyazawa M, Kitahata Y, Iwahashi Y, Ueno M, Hayami S, Murata SI, Shimokawa T, Yamaue H. Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial). Langenbecks Arch Surg. 2020;405:23-33. [PMID: 31993737 DOI: 10.1007/s00423-020-01857-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
93 Ceccon G, Wollring M, Brunn A, Deckert M, Waldschmidt D, Fink GR, Galldiks N. Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine. Case Rep Oncol 2020;13:35-42. [PMID: 32095126 DOI: 10.1159/000504697] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
94 Wu L, Zhou Y, Fan Y, Rao S, Ji Y, Sun J, Li T, Du S, Guo X, Zeng Z, Lou W. Consolidative Chemoradiotherapy After Induced Chemotherapy Is an Optimal Regimen for Locally Advanced Pancreatic Cancer. Front Oncol 2019;9:1543. [PMID: 32039019 DOI: 10.3389/fonc.2019.01543] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
95 Patel R, Fein D, Ramirez CB, Do K, Saif MW. PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session. Pancreas (Fairfax) 2019;3:e5-8. [PMID: 32030362 DOI: 10.17140/POJ-3-e011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
96 De Jesus-Acosta A, Sugar EA, O'Dwyer PJ, Ramanathan RK, Von Hoff DD, Rasheed Z, Zheng L, Begum A, Anders R, Maitra A, McAllister F, Rajeshkumar NV, Yabuuchi S, de Wilde RF, Batukbhai B, Sahin I, Laheru DA. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Br J Cancer. 2020;122:498-505. [PMID: 31857726 DOI: 10.1038/s41416-019-0683-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 55] [Article Influence: 12.0] [Reference Citation Analysis]
97 Oliverius M, Flasarova D, Mohelnikova-Duchonova B, Ehrlichova M, Hlavac V, Kocik M, Strouhal O, Dvorak P, Ojima I, Soucek P. KRAS pathway expression changes in pancreatic cancer models by conventional and experimental taxanes. Mutagenesis 2019;34:403-11. [PMID: 31375828 DOI: 10.1093/mutage/gez021] [Reference Citation Analysis]
98 Zhou J, Zhang L, Zheng H, Ge W, Huang Y, Yan Y, Zhou X, Zhu W, Kong Y, Ding Y, Wang W. Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines. Cancer Med 2020;9:1115-30. [PMID: 31823522 DOI: 10.1002/cam4.2764] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
99 Kamath SD, Kalyan A, Kircher S, Nimeiri H, Fought AJ, Benson A 3rd, Mulcahy M. Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. Oncologist. 2020;25:e808-e815. [PMID: 31740568 DOI: 10.1634/theoncologist.2019-0473] [Cited by in Crossref: 32] [Cited by in F6Publishing: 55] [Article Influence: 10.7] [Reference Citation Analysis]
100 Oneda E, Zaniboni A. Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature. J Clin Med 2019;8:E1922. [PMID: 31717439 DOI: 10.3390/jcm8111922] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
101 Samanta K, Setua S, Kumari S, Jaggi M, Yallapu MM, Chauhan SC. Gemcitabine Combination Nano Therapies for Pancreatic Cancer. Pharmaceutics. 2019;11. [PMID: 31689930 DOI: 10.3390/pharmaceutics11110574] [Cited by in Crossref: 21] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
102 Wang L, Yang L, Chen L, Chen Z. Do Patients Diagnosed with Metastatic Pancreatic Cancer Benefit from Primary Tumor Surgery? A Propensity-Adjusted, Population-Based Surveillance, Epidemiology and End Results (SEER) Analysis. Med Sci Monit 2019;25:8230-41. [PMID: 31677259 DOI: 10.12659/MSM.917106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
103 Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, Nimeiri HS, Munshi HG, Benson AB 3rd, O'Dwyer PJ. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018;4:1707-1712. [PMID: 30178032 DOI: 10.1001/jamaoncol.2018.3277] [Cited by in Crossref: 29] [Cited by in F6Publishing: 39] [Article Influence: 9.7] [Reference Citation Analysis]
104 Jameson GS, Borazanci E, Babiker HM, Poplin E, Niewiarowska AA, Gordon MS, Barrett MT, Rosenthal A, Stoll-D'Astice A, Crowley J, Shemanski L, Korn RL, Ansaldo K, Lebron L, Ramanathan RK, Von Hoff DD. Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial. JAMA Oncol 2019. [PMID: 31580386 DOI: 10.1001/jamaoncol.2019.3394] [Cited by in Crossref: 19] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
105 Lu Z, Weniger M, Jiang K, Boeck S, Zhang K, Bazhin A, Miao Y, Werner J, D'Haese JG. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. Target Oncol 2018;13:447-59. [PMID: 30062609 DOI: 10.1007/s11523-018-0578-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
106 Amantini C, Morelli MB, Nabissi M, Piva F, Marinelli O, Maggi F, Bianchi F, Bittoni A, Berardi R, Giampieri R, Santoni G. Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival.Front Oncol. 2019;9:874. [PMID: 31552188 DOI: 10.3389/fonc.2019.00874] [Cited by in Crossref: 19] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
107 Matsuda Y, Inoue Y, Hiratsuka M, Kawakatsu S, Arai T, Matsueda K, Saiura A, Takazawa Y. Encapsulating fibrosis following neoadjuvant chemotherapy is correlated with outcomes in patients with pancreatic cancer. PLoS One 2019;14:e0222155. [PMID: 31491010 DOI: 10.1371/journal.pone.0222155] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
108 Petrillo A, Pappalardo A, Pompella L, Tirino G, Calabrese F, Laterza MM, Caterino M, Ventriglia A, Orditura M, Conzo G, Molino C, Ciardiello F, Biglietto M, De Vita F. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. Med Oncol 2019;36:83. [PMID: 31444639 DOI: 10.1007/s12032-019-1306-9] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
109 Chan TS, Shaked Y, Tsai KK. Targeting the Interplay Between Cancer Fibroblasts, Mesenchymal Stem Cells, and Cancer Stem Cells in Desmoplastic Cancers. Front Oncol 2019;9:688. [PMID: 31417869 DOI: 10.3389/fonc.2019.00688] [Cited by in Crossref: 37] [Cited by in F6Publishing: 55] [Article Influence: 12.3] [Reference Citation Analysis]
110 Ueda A, Sakai N, Yoshitomi H, Furukawa K, Takayashiki T, Kuboki S, Takano S, Suzuki D, Kagawa S, Mishima T, Nakadai E, Miyazaki M, Ohtsuka M. Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer? World J Surg Oncol 2019;17:124. [PMID: 31315628 DOI: 10.1186/s12957-019-1667-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
111 Noel M, O'Reilly EM, Wolpin BM, Ryan DP, Bullock AJ, Britten CD, Linehan DC, Belt BA, Gamelin EC, Ganguly B, Yin D, Joh T, Jacobs IA, Taylor CT, Lowery MA. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Invest New Drugs 2020;38:800-11. [PMID: 31297636 DOI: 10.1007/s10637-019-00830-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
112 Oh E, Min B, Li Y, Lian C, Hong J, Park GM, Yang B, Cho SY, Hwang YK, Yun CO. Cryopreserved Human Natural Killer Cells Exhibit Potent Antitumor Efficacy against Orthotopic Pancreatic Cancer through Efficient Tumor-Homing and Cytolytic Ability (Running Title: Cryopreserved NK Cells Exhibit Antitumor Effect). Cancers (Basel) 2019;11:E966. [PMID: 31324057 DOI: 10.3390/cancers11070966] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
113 de la Cruz Bonilla M, Stemler KM, Jeter-Jones S, Fujimoto TN, Molkentine J, Asencio Torres GM, Zhang X, Broaddus RR, Taniguchi CM, Piwnica-Worms H. Fasting Reduces Intestinal Radiotoxicity, Enabling Dose-Escalated Radiation Therapy for Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2019;105:537-47. [PMID: 31271824 DOI: 10.1016/j.ijrobp.2019.06.2533] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
114 Ueno M, Nagashima F, Ueno H, Ikeda M, Ohkawa S, Mizuno N, Ioka T, Omuro Y, Nakajima TE, Furuse J. Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Pancreatic Cancer. Intern Med 2019;58:2957-62. [PMID: 31243233 DOI: 10.2169/internalmedicine.2362-18] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
115 North B, Kocher HM, Sasieni P. A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method. BMC Cancer 2019;19:632. [PMID: 31242873 DOI: 10.1186/s12885-019-5801-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
116 Naito Y, Ishikawa H, Sadashima E, Okabe Y, Takahashi K, Kawahara R, Hisaka T, Fukahori M, Ushijima T, Ishida Y, Tanigawa M, Mihara Y, Nakayama M, Kondo R, Kusano H, Takase Y, Abe H, Ogo E, Okuda K, Shimamatsu K, Yano H, Akiba J. Significance of neoadjuvant chemoradiotherapy for borderline resectable pancreatic head cancer: Pathological local invasion and microvessel invasion analysis. Mol Clin Oncol 2019;11:225-33. [PMID: 31423309 DOI: 10.3892/mco.2019.1885] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
117 Hwang HJ, Oh MS, Lee DW, Kuh HJ. Multiplex quantitative analysis of stroma-mediated cancer cell invasion, matrix remodeling, and drug response in a 3D co-culture model of pancreatic tumor spheroids and stellate cells. J Exp Clin Cancer Res 2019;38:258. [PMID: 31200779 DOI: 10.1186/s13046-019-1225-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 42] [Article Influence: 8.3] [Reference Citation Analysis]
118 Tajima H, Ohta T, Okazaki M, Yamaguchi T, Ohbatake Y, Okamoto K, Nakanuma S, Kinoshita J, Makino I, Nakamura K, Miyashita T, Takamura H, Ninomiya I, Fushida S, Nakamura H. Neoadjuvant chemotherapy with gemcitabine-based regimens improves the prognosis of node positive resectable pancreatic head cancer. Mol Clin Oncol 2019;11:157-66. [PMID: 31281650 DOI: 10.3892/mco.2019.1867] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
119 Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15:366-381. [PMID: 29651130 DOI: 10.1038/s41571-018-0007-1] [Cited by in Crossref: 308] [Cited by in F6Publishing: 392] [Article Influence: 102.7] [Reference Citation Analysis]
120 Tsai KK, Chan TS, Shaked Y. Next Viable Routes to Targeting Pancreatic Cancer Stemness: Learning from Clinical Setbacks. J Clin Med 2019;8:E702. [PMID: 31108941 DOI: 10.3390/jcm8050702] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
121 Djanani A, Schmiderer A, Niederreiter L, Niederreiter M, Tilg H. Management of ductal pancreatic cancer: The oncologists view: systemic treatment options in 2018. Eur Surg 2019;51:135-8. [DOI: 10.1007/s10353-019-0583-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
122 Tesfaye AA, Wang H, Hartley ML, He AR, Weiner L, Gabelia N, Kapanadze L, Shezad M, Brody JR, Marshall JL, Pishvaian MJ. A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma. J Pancreat Cancer 2019;5:12-21. [PMID: 31065624 DOI: 10.1089/pancan.2019.0003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
123 Wang ZQ, Zhang F, Deng T, Zhang L, Feng F, Wang FH, Wang W, Wang DS, Luo HY, Xu RH, Ba Y, Li YH. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Cancer Commun (Lond). 2019;39:26. [PMID: 31068222 DOI: 10.1186/s40880-019-0367-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
124 Li F, Yuan H, Zhang H, He M, Liao J, Chen N, Li Y, Zhou S, Palmisano M, Yu A, Pai M, Sun D. Neonatal Fc Receptor (FcRn) Enhances Tissue Distribution and Prevents Excretion of nab-Paclitaxel. Mol Pharm 2019;16:2385-93. [PMID: 31002261 DOI: 10.1021/acs.molpharmaceut.8b01314] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
125 Park J, Park J, Castanares MA, Collins DS, Yeo Y. Magnetophoretic Delivery of a Tumor-Priming Agent for Chemotherapy of Metastatic Murine Breast Cancer. Mol Pharm 2019;16:1864-73. [PMID: 30916974 DOI: 10.1021/acs.molpharmaceut.8b01148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
126 Adachi K, Okuwaki K, Nishiyama R, Kida M, Imaizumi H, Iwai T, Yamauchi H, Kaneko T, Hasegawa R, Miyata E, Kumamoto Y, Koizumi W. A case of extrahepatic bile duct cancer with distant metastases showing pathological complete response to treatment combining gemcitabine and cisplatin. Clin J Gastroenterol 2019;12:466-72. [PMID: 30941639 DOI: 10.1007/s12328-019-00972-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
127 Smeets EMM, Withaar DS, Grootjans W, Hermans JJ, van Laarhoven K, de Geus-Oei LF, Gotthardt M, Aarntzen EHJG. Optimal respiratory-gated [18F]FDG PET/CT significantly impacts the quantification of metabolic parameters and their correlation with overall survival in patients with pancreatic ductal adenocarcinoma. EJNMMI Res 2019;9:24. [PMID: 30868318 DOI: 10.1186/s13550-019-0492-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
128 Hakamada K. Cancer stroma-targeting therapy: A new tool for fighting pancreatic cancer? Ann Gastroenterol Surg 2019;3:120-1. [PMID: 30923780 DOI: 10.1002/ags3.12244] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
129 Kumar Das Majumdar S, Kumar Muduly D, Mishra S, Mohapatra CRR, Bunger D, Khan MA. Management of primary squamous cell carcinoma of the pancreas with a nanosomal paclitaxel lipid suspension-based regimen: A case report. Mol Clin Oncol 2019;10:430-4. [PMID: 30931112 DOI: 10.3892/mco.2019.1814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
130 Ning Z, Xie J, Chen Q, Zhang C, Xu L, Song L, Meng Z. HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients. Onco Targets Ther 2019;12:1021-9. [PMID: 30774386 DOI: 10.2147/OTT.S185424] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
131 Hasan S, Jacob R, Manne U, Paluri R. Advances in pancreatic cancer biomarkers. Oncol Rev 2019;13:410. [PMID: 31044028 DOI: 10.4081/oncol.2019.410] [Cited by in Crossref: 39] [Cited by in F6Publishing: 53] [Article Influence: 13.0] [Reference Citation Analysis]
132 Cho SY, Chae J, Na D, Kang W, Lee A, Min S, Kang J, Choi B, Lee J, Sung CO, Chuang JH, Lee C, Lee WS, Park H, Kim JI. Unstable Genome and Transcriptome Dynamics during Tumor Metastasis Contribute to Therapeutic Heterogeneity in Colorectal Cancers. Clin Cancer Res 2019;25:2821-34. [PMID: 30670495 DOI: 10.1158/1078-0432.CCR-18-3460] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
133 Balachandran VP, Beatty GL, Dougan SK. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. Gastroenterology 2019;156:2056-72. [PMID: 30660727 DOI: 10.1053/j.gastro.2018.12.038] [Cited by in Crossref: 95] [Cited by in F6Publishing: 155] [Article Influence: 31.7] [Reference Citation Analysis]
134 Ettrich TJ, Berger AW, Perkhofer L, Daum S, König A, Dickhut A, Wittel U, Wille K, Geissler M, Algül H, Gallmeier E, Atzpodien J, Kornmann M, Muche R, Prasnikar N, Tannapfel A, Reinacher-Schick A, Uhl W, Seufferlein T. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. BMC Cancer 2018;18:1298. [PMID: 30594153 DOI: 10.1186/s12885-018-5183-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 40] [Article Influence: 6.5] [Reference Citation Analysis]
135 Li J, Hu B, Wang T, Huang W, Ma C, Zhao Q, Zhuo L, Zhang T, Jiang Y. C-Src confers resistance to mitotic stress through inhibition DMAP1/Bub3 complex formation in pancreatic cancer. Mol Cancer 2018;17:174. [PMID: 30553276 DOI: 10.1186/s12943-018-0919-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
136 Ishii N, Araki K, Yokobori T, Hagiwara K, Gantumur D, Yamanaka T, Handa T, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N, Harimoto N, Masamune A, Umezawa K, Kuwano H, Shirabe K. Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts. Cancer Sci 2019;110:334-44. [PMID: 30353606 DOI: 10.1111/cas.13847] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
137 Ielpo B. The issue of how predict survival of patients affected by locally advanced pancreatic cancer. Ann Transl Med 2018;6:S128. [PMID: 30740449 DOI: 10.21037/atm.2018.12.41] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
138 Veenstra VL, Damhofer H, Waasdorp C, van Rijssen LB, van de Vijver MJ, Dijk F, Wilmink HW, Besselink MG, Busch OR, Chang DK, Bailey PJ, Biankin AV, Kocher HM, Medema JP, Li JS, Jiang R, Pierce DW, van Laarhoven HWM, Bijlsma MF. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis 2018;7:87. [PMID: 30442938 DOI: 10.1038/s41389-018-0096-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
139 Meng Q, Valentini D, Rao M, Moro CF, Paraschoudi G, Jäger E, Dodoo E, Rangelova E, Del Chiaro M, Maeurer M. Neoepitope targets of tumour-infiltrating lymphocytes from patients with pancreatic cancer. Br J Cancer 2019;120:97-108. [PMID: 30377343 DOI: 10.1038/s41416-018-0262-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
140 Zhu X, Li F, Shi D, Ju X, Cao Y, Shen Y, Cao F, Qing S, Fang F, Jia Z, Zhang H. Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pancreatic cancer. Cancer Manag Res 2018;10:4805-15. [PMID: 30425574 DOI: 10.2147/CMAR.S166713] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
141 Chen H, He R, Shi X, Zhou M, Zhao C, Zhang H, Qin R. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone. BMC Cancer 2018;18:1034. [PMID: 30352573 DOI: 10.1186/s12885-018-4948-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
142 Mahipal A, Tella SH, Kommalapati A, Goyal G, Soares H, Neuger A, Copolla D, Kim J, Kim R. Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Invest New Drugs 2019;37:473-81. [PMID: 30298303 DOI: 10.1007/s10637-018-0676-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
143 Kawano M, Kaino S, Amano S, Shinoda S, Suenaga S, Sen-Yo M, Sakaida I. Heat Shock Protein 27 Expression in EUS-FNA Samples Can Predict Gemcitabine Sensitivity in Pancreatic Cancer. In Vivo. 2018;32:637-642. [PMID: 29695571 DOI: 10.21873/invivo.11286] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
144 Kokkali S, Tripodaki ES, Drizou M, Stefanou D, Magou E, Zylis D, Kapiris M, Nasi D, Georganta C, Ardavanis A. Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer. In Vivo 2018;32:653-7. [PMID: 29695574 DOI: 10.21873/invivo.11289] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
145 Kanat O, Ertas H. Shattering the castle walls: Anti-stromal therapy for pancreatic cancer. World J Gastrointest Oncol 2018; 10(8): 202-210 [PMID: 30147846 DOI: 10.4251/wjgo.v10.i8.202] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
146 Williet N, Di Bernardo T, Vernet C, Roche LS, Muron T, Roblin X, Magne N, Phelip JM. Intensification of induction chemotherapy before consolidation chemoradiotherapy improves progression-free survival and time without treatment in patients with locally advanced pancreatic cancers. Oncotarget 2018;9:31999-2009. [PMID: 30174792 DOI: 10.18632/oncotarget.25877] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
147 Bruera G, Massacese S, Candria S, Galvano A, Manetta R, Giordano AV, Carducci S, Di Sibio A, Ciacco E, Russo A, Ricevuto E; Oncology Network ASL1 Abruzzo, Italy. Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. Oncotarget 2018;9:31861-76. [PMID: 30159128 DOI: 10.18632/oncotarget.25870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
148 Cai W, Ratnayake R, Gerber MH, Chen QY, Yu Y, Derendorf H, Trevino JG, Luesch H. Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model. Invest New Drugs 2019;37:364-74. [PMID: 30073464 DOI: 10.1007/s10637-018-0647-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
149 Zhang L, Qin Y, Zhang Z, Fan F, Huang C, Lu L, Wang H, Jin X, Zhao H, Kong D, Wang C, Sun H, Leng X, Zhu D. Dual pH/reduction-responsive hybrid polymeric micelles for targeted chemo-photothermal combination therapy. Acta Biomater 2018;75:371-85. [PMID: 29777957 DOI: 10.1016/j.actbio.2018.05.026] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 12.0] [Reference Citation Analysis]
150 Shinoda S, Kaino S, Amano S, Harima H, Matsumoto T, Fujisawa K, Takami T, Yamamoto N, Yamasaki T, Sakaida I. Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo. Oncotarget 2018;9:28434-44. [PMID: 29983871 DOI: 10.18632/oncotarget.25421] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
151 Cintas C, Douché T, Therville N, Arcucci S, Ramos-Delgado F, Basset C, Thibault B, Guillermet-Guibert J. Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics. Cancers (Basel) 2018;10:E174. [PMID: 29865155 DOI: 10.3390/cancers10060174] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
152 Izumchenko E, Paz K, Ciznadija D, Sloma I, Katz A, Vasquez-Dunddel D, Ben-Zvi I, Stebbing J, McGuire W, Harris W, Maki R, Gaya A, Bedi A, Zacharoulis S, Ravi R, Wexler LH, Hoque MO, Rodriguez-Galindo C, Pass H, Peled N, Davies A, Morris R, Hidalgo M, Sidransky D. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann Oncol 2017;28:2595-605. [PMID: 28945830 DOI: 10.1093/annonc/mdx416] [Cited by in Crossref: 112] [Cited by in F6Publishing: 134] [Article Influence: 28.0] [Reference Citation Analysis]
153 Mahalingam D, Goel S, Aparo S, Patel Arora S, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Gutierrez A, Coffey M, Nawrocki ST, Nuovo G, Mita MM. A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 2018;10:E160. [PMID: 29799479 DOI: 10.3390/cancers10060160] [Cited by in Crossref: 50] [Cited by in F6Publishing: 56] [Article Influence: 12.5] [Reference Citation Analysis]
154 Zhu X, Li F, Liu W, Shi D, Ju X, Cao Y, Shen Y, Cao F, Qing S, Fang F, Jia Z, Zhang H. Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: A propensity score-matched analysis of a prospectively collected database. Cancer Manag Res 2018;10:1295-304. [PMID: 29872342 DOI: 10.2147/CMAR.S163655] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
155 Zhu X, Shi D, Li F, Ju X, Cao Y, Shen Y, Cao F, Qing S, Fang F, Jia Z, Zhang H. Prospective analysis of different combined regimens of stereotactic body radiation therapy and chemotherapy for locally advanced pancreatic cancer. Cancer Med 2018. [PMID: 29771005 DOI: 10.1002/cam4.1553] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
156 He X, Chen X, Liu L, Zhang Y, Lu Y, Zhang Y, Chen Q, Ruan C, Guo Q, Li C, Sun T, Jiang C. Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy. Adv Sci (Weinh) 2018;5:1701070. [PMID: 29876225 DOI: 10.1002/advs.201701070] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 13.3] [Reference Citation Analysis]
157 Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer 2018;118:1419-24. [PMID: 29695765 DOI: 10.1038/s41416-018-0068-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
158 Wu ST, Fowler AJ, Garmon CB, Fessler AB, Ogle JD, Grover KR, Allen BC, Williams CD, Zhou R, Yazdanifar M, Ogle CA, Mukherjee P. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles. BMC Cancer 2018;18:457. [PMID: 29685122 DOI: 10.1186/s12885-018-4393-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
159 Hall BR, Cannon A, Atri P, Wichman CS, Smith LM, Ganti AK, Are C, Sasson AR, Kumar S, Batra SK. Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. Oncotarget 2018;9:19396-405. [PMID: 29721211 DOI: 10.18632/oncotarget.25036] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
160 Tajima H, Okazaki M, Yamaguchi T, Ohbatake Y, Okamoto K, Nakanuma S, Terai S, Sakai S, Kinoshita J, Makino I, Nakamura K, Hayashi H, Oyama K, Inokuchi M, Miyashita T, Takamura H, Ninomiya I, Fushida S, Ohta T. Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer. Mol Clin Oncol 2018;8:623-7. [PMID: 29556385 DOI: 10.3892/mco.2018.1579] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
161 Saito N, Shirai Y, Uwagawa T, Horiuchi T, Sugano H, Haruki K, Shiba H, Ohashi T, Yanaga K. Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo. Oncotarget 2018;9:15780-91. [PMID: 29644009 DOI: 10.18632/oncotarget.24608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
162 Solomon BL, Garrido-Laguna I. Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. Future Oncol 2018;14:947-62. [PMID: 29542354 DOI: 10.2217/fon-2017-0597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
163 Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. Target Oncol 2017;12:309-21. [PMID: 28353074 DOI: 10.1007/s11523-017-0486-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
164 Bousquet G, El Bouchtaoui M, Sophie T, Leboeuf C, de Bazelaire C, Ratajczak P, Giacchetti S, de Roquancourt A, Bertheau P, Verneuil L, Feugeas JP, Espié M, Janin A. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer. Oncotarget 2017;8:35205-21. [PMID: 28445132 DOI: 10.18632/oncotarget.16925] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
165 Thota R, Maitra A, Berlin JD. Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer? Pancreas 2017;46:143-50. [PMID: 28085753 DOI: 10.1097/MPA.0000000000000753] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
166 Matkar PN, Singh KK, Rudenko D, Kim YJ, Kuliszewski MA, Prud'homme GJ, Hedley DW, Leong-Poi H. Novel regulatory role of neuropilin-1 in endothelial-to-mesenchymal transition and fibrosis in pancreatic ductal adenocarcinoma. Oncotarget 2016;7:69489-506. [PMID: 27542226 DOI: 10.18632/oncotarget.11060] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
167 Yu IS, Cheung WY. A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. Can J Gastroenterol Hepatol 2018;2018:1863535. [PMID: 29623263 DOI: 10.1155/2018/1863535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
168 Johnson BA 3rd, Yarchoan M, Lee V, Laheru DA, Jaffee EM. Strategies for Increasing Pancreatic Tumor Immunogenicity. Clin Cancer Res. 2017;23:1656-1669. [PMID: 28373364 DOI: 10.1158/1078-0432.ccr-16-2318] [Cited by in Crossref: 68] [Cited by in F6Publishing: 83] [Article Influence: 17.0] [Reference Citation Analysis]
169 Baliyan V, Kordbacheh H, Parakh A, Kambadakone A. Response assessment in pancreatic ductal adenocarcinoma: role of imaging. Abdom Radiol (NY) 2018;43:435-44. [PMID: 29243123 DOI: 10.1007/s00261-017-1434-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
170 Steins A, Ebbing EA, Pistorius MCM, Waasdorp C, Krishnadath KK, Medema JP, Wilmink JW, Mathôt RAA, Bijlsma MF, van Laarhoven HWM. Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel. Drug Deliv 2017;24:1801-10. [PMID: 29172757 DOI: 10.1080/10717544.2017.1406559] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
171 Chen C, Yu G, Xiao W, Xing M, Ni J, Wan R, Hu G. Thalidomide inhibits proliferation and epithelial-mesenchymal transition by modulating CD133 expression in pancreatic cancer cells. Oncol Lett 2017;14:8206-12. [PMID: 29344263 DOI: 10.3892/ol.2017.7213] [Reference Citation Analysis]
172 Lee JH, Kim SK, Khawar IA, Jeong SY, Chung S, Kuh HJ. Microfluidic co-culture of pancreatic tumor spheroids with stellate cells as a novel 3D model for investigation of stroma-mediated cell motility and drug resistance. J Exp Clin Cancer Res 2018;37:4. [PMID: 29329547 DOI: 10.1186/s13046-017-0654-6] [Cited by in Crossref: 67] [Cited by in F6Publishing: 84] [Article Influence: 16.8] [Reference Citation Analysis]
173 Sakai Y, Iwai T, Shimura K, Gon K, Koizumi K, Ijima M, Chiba K, Nakatani S, Sugiyama H, Tsuyuguchi T, Kamisawa T, Maetani I, Kida M. Safety and efficacy of metallic stent for unresectable distal malignant biliary obstruction in elderly patients. World J Gastroenterol 2018; 24(1): 69-75 [PMID: 29358883 DOI: 10.3748/wjg.v24.i1.69] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
174 Ramanathan RK, Weiss GJ, Posner RG, Rajeshkumar NV, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites EC, Hlavacek WS, Gatalica Z, Xiu J, Hidalgo M, Von Hoff DD, Barrett MT. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. J Gastrointest Oncol 2017;8:925-35. [PMID: 29299351 DOI: 10.21037/jgo.2017.09.05] [Reference Citation Analysis]
175 Zhang Y, Sun T, Jiang C. Biomacromolecules as carriers in drug delivery and tissue engineering. Acta Pharm Sin B 2018;8:34-50. [PMID: 29872621 DOI: 10.1016/j.apsb.2017.11.005] [Cited by in Crossref: 167] [Cited by in F6Publishing: 135] [Article Influence: 41.8] [Reference Citation Analysis]
176 Krantz BA, O'Reilly EM. Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality? Clin Cancer Res 2018;24:2241-50. [PMID: 29269376 DOI: 10.1158/1078-0432.CCR-16-3169] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
177 Elia A, Henry-Grant R, Adiseshiah C, Marboeuf C, Buckley RJ, Clemens MJ, Mudan S, Pyronnet S. Implication of 4E-BP1 protein dephosphorylation and accumulation in pancreatic cancer cell death induced by combined gemcitabine and TRAIL. Cell Death Dis 2017;8:3204. [PMID: 29233971 DOI: 10.1038/s41419-017-0001-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
178 Bullock A, Stuart K, Jacobus S, Abrams T, Wadlow R, Goldstein M, Miksad R. Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma.J Gastrointest Oncol. 2017;8:945-952. [PMID: 29299353 DOI: 10.21037/jgo.2017.06.06] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
179 Katsaounis P, Kotsakis A, Kentepozidis N, Polyzos A, Bakogeorgos M, Koinis F, Vamvakas L, Vardakis N, Kalbakis K, Boukovinas I, Varthalitis II, Prinarakis E, Georgoulias V, Souglakos J. Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group. Ann Gastroenterol 2018;31:65-70. [PMID: 29333068 DOI: 10.20524/aog.2017.0215] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
180 Nakajima M, Yoshino S, Kanekiyo S, Maeda N, Sakamoto K, Tsunedomi R, Suzuki N, Takeda S, Yamamoto S, Hazama S, Hoshii Y, Oga A, Itoh H, Ueno T, Nagano H. High secreted protein acidic and rich in cysteine expression in peritumoral fibroblasts predicts better prognosis in patients with resectable gastric cancer. Oncol Lett. 2018;15:803-812. [PMID: 29403557 DOI: 10.3892/ol.2017.7418] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
181 Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, Zeb A. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine. 2017;12:7291-7309. [PMID: 29042776 DOI: 10.2147/ijn.s146315] [Cited by in Crossref: 385] [Cited by in F6Publishing: 124] [Article Influence: 77.0] [Reference Citation Analysis]
182 Manzur A, Oluwasanmi A, Moss D, Curtis A, Hoskins C. Nanotechnologies in Pancreatic Cancer Therapy. Pharmaceutics 2017;9:E39. [PMID: 28946666 DOI: 10.3390/pharmaceutics9040039] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
183 Chatterjee M, Ben-Josef E, Robb R, Vedaie M, Seum S, Thirumoorthy K, Palanichamy K, Harbrecht M, Chakravarti A, Williams TM. Caveolae-Mediated Endocytosis Is Critical for Albumin Cellular Uptake and Response to Albumin-Bound Chemotherapy. Cancer Res 2017;77:5925-37. [PMID: 28923854 DOI: 10.1158/0008-5472.CAN-17-0604] [Cited by in Crossref: 59] [Cited by in F6Publishing: 72] [Article Influence: 11.8] [Reference Citation Analysis]
184 Chen Y, Li J, Chen S, Zhang Y, Hu Y, Zhang G, Yan X, Jiao S. Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer. Sci Rep 2017;7:10760. [PMID: 28883517 DOI: 10.1038/s41598-017-11404-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
185 Aguilera KY, Huang H, Du W, Hagopian MM, Wang Z, Hinz S, Hwang TH, Wang H, Fleming JB, Castrillon DH, Ren X, Ding K, Brekken RA. Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther 2017;16:2473-85. [PMID: 28864681 DOI: 10.1158/1535-7163.MCT-16-0834] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 9.4] [Reference Citation Analysis]
186 Giordano G, Pancione M, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D’Andrea MR. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World J Gastroenterol 2017; 23(32): 5875-5886 [PMID: 28932079 DOI: 10.3748/wjg.v23.i32.5875] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 47] [Article Influence: 11.4] [Reference Citation Analysis]
187 Malgerud L, Lindberg J, Wirta V, Gustafsson-Liljefors M, Karimi M, Moro CF, Stecker K, Picker A, Huelsewig C, Stein M, Bohnert R, Del Chiaro M, Haas SL, Heuchel RL, Permert J, Maeurer MJ, Brock S, Verbeke CS, Engstrand L, Jackson DB, Grönberg H, Löhr JM. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. Mol Oncol 2017;11:1413-29. [PMID: 28675654 DOI: 10.1002/1878-0261.12108] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
188 Korn RL, Von Hoff DD, Borad MJ, Renschler MF, McGovern D, Curtis Bay R, Ramanathan RK. 18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer. Cancer Imaging 2017;17:23. [PMID: 28774338 DOI: 10.1186/s40644-017-0125-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
189 Lau SC, Cheung WY. Evolving treatment landscape for early and advanced pancreatic cancer. World J Gastrointest Oncol 2017; 9(7): 281-292 [PMID: 28808501 DOI: 10.4251/wjgo.v9.i7.281] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
190 Feng K, Liu Y, Guo Y, Qiu J, Wu Z, Dai H, Yang Q, Wang Y, Han W. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell 2018;9:838-47. [PMID: 28710747 DOI: 10.1007/s13238-017-0440-4] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 15.0] [Reference Citation Analysis]
191 Martín M, Chacón JI, Antón A, Plazaola A, García-Martínez E, Seguí MA, Sánchez-Rovira P, Palacios J, Calvo L, Esteban C, Espinosa E, Barnadas A, Batista N, Guerrero A, Muñoz M, Romio E, Rodríguez-Martín C, Caballero R, Casas MI, Rojo F, Carrasco E, Antolín S. Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. Oncologist 2017;22:1301-8. [PMID: 28701571 DOI: 10.1634/theoncologist.2017-0052] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
192 Borsoi C, Leonard F, Lee Y, Zaid M, Elganainy D, Alexander JF, Kai M, Liu YT, Kang Y, Liu X, Koay EJ, Ferrari M, Godin B, Yokoi K. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Lett 2017;403:296-304. [PMID: 28687352 DOI: 10.1016/j.canlet.2017.06.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
193 Von Hoff DD, Renschler MF. Letter to the Editor Re: Ahn DH, Krishna K, Blazer M, et al. "A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis." Ther Adv Med Oncol https://doi.org/10.1177/1758834016676011. Ther Adv Med Oncol 2017;9:441-3. [PMID: 28607582 DOI: 10.1177/1758834017699772] [Reference Citation Analysis]
194 Veenstra VL, Damhofer H, Waasdorp C, Steins A, Kocher HM, Medema JP, van Laarhoven HW, Bijlsma MF. Stromal SPOCK1 supports invasive pancreatic cancer growth. Mol Oncol 2017;11:1050-64. [PMID: 28486750 DOI: 10.1002/1878-0261.12073] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
195 Verdaguer H, Saurí T, Macarulla T. Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment. J Gastrointest Oncol 2017;8:405-17. [PMID: 28736628 DOI: 10.21037/jgo.2016.11.15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
196 Kurimoto M, Kimura M, Usami E, Iwai M, Hirose T, Kawachi S, Yoshimura T. Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer. Mol Clin Oncol 2017;7:125-30. [PMID: 28685089 DOI: 10.3892/mco.2017.1278] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
197 Kasai S, Sasaki T, Watanabe A, Nishiya M, Yasuhira S, Shibazaki M, Maesawa C. Bcl-2/Bcl-xL inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death. Oncol Lett 2017;14:903-8. [PMID: 28693250 DOI: 10.3892/ol.2017.6211] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
198 Sun Q, Zhou Z, Qiu N, Shen Y. Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization. Adv Mater 2017;29. [PMID: 28234430 DOI: 10.1002/adma.201606628] [Cited by in Crossref: 529] [Cited by in F6Publishing: 543] [Article Influence: 105.8] [Reference Citation Analysis]
199 Tajima H, Ohta T, Shinbashi H, Hirose A, Okazaki M, Yamaguchi T, Ohbatake Y, Okamoto K, Nakanuma S, Sakai S, Kinoshita J, Makino I, Nakamura K, Hayashi H, Oyama K, Inokuchi M, Miyashita T, Takamura H, Ninomiya I, Fushida S, Nakamura H. Phase I study of weekly palliative chemotherapy with low-dose third-line paclitaxel for biliary tract cancer. Mol Clin Oncol 2017;6:753-7. [PMID: 28529750 DOI: 10.3892/mco.2017.1206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
200 von Ahrens D, Bhagat TD, Nagrath D, Maitra A, Verma A. The role of stromal cancer-associated fibroblasts in pancreatic cancer. J Hematol Oncol 2017;10:76. [PMID: 28351381 DOI: 10.1186/s13045-017-0448-5] [Cited by in Crossref: 144] [Cited by in F6Publishing: 186] [Article Influence: 28.8] [Reference Citation Analysis]
201 Toyota K, Murakami Y, Kondo N, Uemura K, Nakagawa N, Takahashi S, Sueda T. Impact of Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression on Prognosis After Surgical Resection for Biliary Carcinoma. J Gastrointest Surg 2017;21:990-9. [DOI: 10.1007/s11605-017-3407-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
202 Kim G. nab-Paclitaxel for the treatment of pancreatic cancer. Cancer Manag Res 2017;9:85-96. [PMID: 28356771 DOI: 10.2147/CMAR.S127840] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
203 Laquente B, Lopez-Martin J, Richards D, Illerhaus G, Chang DZ, Kim G, Stella P, Richel D, Szcylik C, Cascinu S, Frassineti GL, Ciuleanu T, Hurt K, Hynes S, Lin J, Lin AB, Von Hoff D, Calvo E. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer 2017;17:137. [PMID: 28202004 DOI: 10.1186/s12885-017-3131-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
204 Fasano M, Della Corte CM, Vicidomini G, Scotti V, Rambaldi PF, Fiorelli A, Accardo M, De Vita F, Santini M, Ciardiello F, Morgillo F. Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review. Oncol Lett 2016;12:4505-9. [PMID: 28105159 DOI: 10.3892/ol.2016.5279] [Reference Citation Analysis]
205 Ariake K, Motoi F, Mizuma M, Murakami K, Takadate T, Ohtsuka H, Fukase K, Masuda K, Hayashi H, Nakagawa K, Sakata N, Morikawa T, Maeda S, Naitoh T, Egawa S, Unno M. Locally advanced pancreatic cancer successfully treated by distal pancreatectomy with celiac axis resection (DP-CAR) after S-1 with radiation therapy followed by gemcitabine/nab-paclitaxel therapy: a case report. Surg Case Rep 2017;3:15. [PMID: 28101795 DOI: 10.1186/s40792-017-0290-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
206 Cullis J, Siolas D, Avanzi A, Barui S, Maitra A, Bar-Sagi D. Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer. Cancer Immunol Res. 2017;5:182-190. [PMID: 28108630 DOI: 10.1158/2326-6066.cir-16-0125] [Cited by in Crossref: 61] [Cited by in F6Publishing: 81] [Article Influence: 12.2] [Reference Citation Analysis]
207 Parsels LA, Tanska DM, Parsels JD, Zabludoff SD, Cuneo KC, Lawrence TS, Maybaum J, Morgan MA. Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry. Cell Cycle 2016;15:730-9. [PMID: 26890478 DOI: 10.1080/15384101.2016.1148841] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
208 Ghosn M, Ibrahim T, Assi T, El Rassy E, Kourie HR, Kattan J. Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. World J Gastroenterol 2016; 22(46): 10124-10130 [PMID: 28028360 DOI: 10.3748/wjg.v22.i46.10124] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
209 Oziel-Taieb S, Faure M, Gilabert M, Autret A, Turrini O, Moureau-Zabotto L, Giovannini M, Rousseau F, Raoul JL. Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients. J Gastrointest Cancer 2016;47:15-9. [PMID: 26545612 DOI: 10.1007/s12029-015-9774-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
210 Zhu L, Staley C, Kooby D, El-Rays B, Mao H, Yang L. Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy. Cancer Lett 2017;388:139-48. [PMID: 27916607 DOI: 10.1016/j.canlet.2016.11.030] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
211 Sukharamwala P, Hennessey D, Wood T, Singh S, Ryan C, Rosemurgy A. Molecular profiles in foregut oncology. Cancer Genet 2016;209:537-53. [PMID: 27887938 DOI: 10.1016/j.cancergen.2016.09.008] [Reference Citation Analysis]
212 Ormanns S, Haas M, Baechmann S, Altendorf-Hofmann A, Remold A, Quietzsch D, Clemens MR, Bentz M, Geissler M, Lambertz H, Kruger S, Kirchner T, Heinemann V, Boeck S. Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials. Br J Cancer. 2016;115:1520-1529. [PMID: 27802454 DOI: 10.1038/bjc.2016.355] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
213 Komiya K, Nakamura T, Nakashima C, Takahashi K, Umeguchi H, Watanabe N, Sato A, Takeda Y, Kimura S, Sueoka-Aragane N. SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer. Onco Targets Ther 2016;9:6663-8. [PMID: 27822069 DOI: 10.2147/OTT.S114492] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
214 El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol Ther 2015;16:1726-37. [PMID: 26553611 DOI: 10.1080/15384047.2015.1113356] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 7.7] [Reference Citation Analysis]
215 Ireland L, Santos A, Ahmed MS, Rainer C, Nielsen SR, Quaranta V, Weyer-Czernilofsky U, Engle DD, Perez-Mancera PA, Coupland SE, Taktak A, Bogenrieder T, Tuveson DA, Campbell F, Schmid MC, Mielgo A. Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors. Cancer Res 2016;76:6851-63. [PMID: 27742686 DOI: 10.1158/0008-5472.CAN-16-1201] [Cited by in Crossref: 119] [Cited by in F6Publishing: 127] [Article Influence: 19.8] [Reference Citation Analysis]
216 Vijayvergia N, Cohen SJ. Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer? J Gastrointest Oncol 2016;7:727-37. [PMID: 27747087 DOI: 10.21037/jgo.2016.08.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
217 Wang HY, Yao ZH, Tang H, Zhao Y, Zhang XS, Yao SN, Yang SJ, Liu YY. Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma. Onco Targets Ther 2016;9:5663-9. [PMID: 27713635 DOI: 10.2147/OTT.S108580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
218 Varghese AM, Lowery MA, Yu KH, O'Reilly EM. Current management and future directions in metastatic pancreatic adenocarcinoma. Cancer 2016;122:3765-75. [PMID: 27649047 DOI: 10.1002/cncr.30342] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
219 Aiello NM, Bajor DL, Norgard RJ, Sahmoud A, Bhagwat N, Pham MN, Cornish TC, Iacobuzio-Donahue CA, Vonderheide RH, Stanger BZ. Metastatic progression is associated with dynamic changes in the local microenvironment. Nat Commun 2016;7:12819. [PMID: 27628423 DOI: 10.1038/ncomms12819] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 11.8] [Reference Citation Analysis]
220 Schneeberger VE, Allaj V, Gardner EE, Poirier JT, Rudin CM. Quantitation of Murine Stroma and Selective Purification of the Human Tumor Component of Patient-Derived Xenografts for Genomic Analysis. PLoS One 2016;11:e0160587. [PMID: 27611664 DOI: 10.1371/journal.pone.0160587] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
221 De Vita F, Ventriglia J, Febbraro A, Laterza MM, Fabozzi A, Savastano B, Petrillo A, Diana A, Giordano G, Troiani T, Conzo G, Galizia G, Ciardiello F, Orditura M. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. BMC Cancer 2016;16:709. [PMID: 27590845 DOI: 10.1186/s12885-016-2671-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
222 Harima H, Kaino S, Takami T, Shinoda S, Matsumoto T, Fujisawa K, Yamamoto N, Yamasaki T, Sakaida I. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo. BMC Cancer 2016;16:702. [PMID: 27582255 DOI: 10.1186/s12885-016-2744-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
223 Mohelnikova-Duchonova B, Kocik M, Duchonova B, Brynychova V, Oliverius M, Hlavsa J, Honsova E, Mazanec J, Kala Z, Ojima I, Hughes DJ, Doherty JE, Murray HA, Crockard MA, Lemstrova R, Soucek P. Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. Pharmacogenomics J 2017;17:452-60. [PMID: 27573236 DOI: 10.1038/tpj.2016.55] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
224 Unseld M, Scheithauer W, Weigl R, Kornek G, Stranzl N, Bianconi D, Brunauer G, Steger G, Zielinski CC, Prager GW. Nab-paclitaxel as alternative treatment regimen in advanced cholangiocellular carcinoma. J Gastrointest Oncol. 2016;7:588-594. [PMID: 27563449 DOI: 10.21037/jgo.2016.05.01] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
225 Kausar T, Schreiber JS, Karnak D, Parsels LA, Parsels JD, Davis MA, Zhao L, Maybaum J, Lawrence TS, Morgan MA. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair. Neoplasia. 2015;17:757-766. [PMID: 26585231 DOI: 10.1016/j.neo.2015.09.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 47] [Article Influence: 6.2] [Reference Citation Analysis]
226 Hsueh CT, Selim JH, Tsai JY, Hsueh CT. Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma. World J Gastroenterol 2016; 22(31): 7080-7090 [PMID: 27610018 DOI: 10.3748/wjg.v22.i31.7080] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
227 Caparello C, Meijer LL, Garajova I, Falcone A, Le Large TY, Funel N, Kazemier G, Peters GJ, Vasile E, Giovannetti E. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World J Gastroenterol 2016; 22(31): 6987-7005 [PMID: 27610011 DOI: 10.3748/wjg.v22.i31.6987] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 38] [Article Influence: 8.3] [Reference Citation Analysis]
228 Davis EJ, Zhao L, Lucas DR, Schuetze SM, Baker LH, Zalupski MM, Thomas D, Chugh R. SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy. BMC Cancer 2016;16:663. [PMID: 27544129 DOI: 10.1186/s12885-016-2694-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
229 Au M, Emeto TI, Power J, Vangaveti VN, Lai HC. Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials. Biomedicines 2016;4:E20. [PMID: 28536387 DOI: 10.3390/biomedicines4030020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
230 Adiseshaiah PP, Crist RM, Hook SS, McNeil SE. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol 2016;13:750-65. [PMID: 27531700 DOI: 10.1038/nrclinonc.2016.119] [Cited by in Crossref: 115] [Cited by in F6Publishing: 125] [Article Influence: 19.2] [Reference Citation Analysis]
231 Meng F, Han N, Yeo Y. Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy. Expert Opin Drug Deliv 2017;14:427-46. [PMID: 27476442 DOI: 10.1080/17425247.2016.1218464] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
232 Rajeshkumar NV, Yabuuchi S, Pai SG, Tong Z, Hou S, Bateman S, Pierce DW, Heise C, Von Hoff DD, Maitra A. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. Br J Cancer. 2016;115:442-453. [PMID: 27441498 DOI: 10.1038/bjc.2016.215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
233 Huang Y, Liang W, Yang Y, Zhao L, Zhao H, Wu X, Zhao Y, Zhang Y, Zhang L. Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma. BMC Cancer 2016;16:464. [PMID: 27411683 DOI: 10.1186/s12885-016-2517-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
234 Reni M, Balzano G, Zanon S, Passoni P, Nicoletti R, Arcidiacono PG, Pepe G, Doglioni C, Fugazza C, Ceraulo D, Falconi M, Gianni L. Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma. Br J Cancer. 2016;115:290-296. [PMID: 27404453 DOI: 10.1038/bjc.2016.209] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
235 Polireddy K, Chen Q. Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. J Cancer 2016;7:1497-514. [PMID: 27471566 DOI: 10.7150/jca.14922] [Cited by in Crossref: 35] [Cited by in F6Publishing: 48] [Article Influence: 5.8] [Reference Citation Analysis]
236 Heeg S, Das KK, Reichert M, Bakir B, Takano S, Caspers J, Aiello NM, Wu K, Neesse A, Maitra A, Iacobuzio-Donahue CA, Hicks P, Rustgi AK. ETS-Transcription Factor ETV1 Regulates Stromal Expansion and Metastasis in Pancreatic Cancer. Gastroenterology 2016;151:540-553.e14. [PMID: 27318148 DOI: 10.1053/j.gastro.2016.06.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
237 Fotopoulos G, Syrigos K, Saif MW. Genetic factors affecting patient responses to pancreatic cancer treatment. Ann Gastroenterol 2016;29:466-76. [PMID: 27708512 DOI: 10.20524/aog.2016.0056] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
238 Byrne KT, Vonderheide RH. CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. Cell Rep 2016;15:2719-32. [PMID: 27292635 DOI: 10.1016/j.celrep.2016.05.058] [Cited by in Crossref: 118] [Cited by in F6Publishing: 100] [Article Influence: 19.7] [Reference Citation Analysis]
239 Faisal F, Tsai HL, Blackford A, Olino K, Xia C, De Jesus-Acosta A, Le DT, Cosgrove D, Azad N, Rasheed Z, Diaz LA Jr, Donehower R, Laheru D, Hruban RH, Fishman EK, Edil BH, Schulick R, Wolfgang C, Herman J, Zheng L. Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. Am J Clin Oncol 2016;39:18-26. [PMID: 24351782 DOI: 10.1097/COC.0000000000000022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
240 Kirby MK, Ramaker RC, Gertz J, Davis NS, Johnston BE, Oliver PG, Sexton KC, Greeno EW, Christein JD, Heslin MJ, Posey JA, Grizzle WE, Vickers SM, Buchsbaum DJ, Cooper SJ, Myers RM. RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. Mol Oncol. 2016;10:1169-1182. [PMID: 27282075 DOI: 10.1016/j.molonc.2016.05.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
241 Zhang X, Wojtkowiak JW, Martinez GV, Cornnell HH, Hart CP, Baker AF, Gillies R. MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts. PLoS One 2016;11:e0155289. [PMID: 27227903 DOI: 10.1371/journal.pone.0155289] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
242 Lo Re G, Santeufemia DA, Foltran L, Bidoli E, Basso SM, Lumachi F. Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience. Oncotarget 2015;6:8255-60. [PMID: 25779664 DOI: 10.18632/oncotarget.3143] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
243 Kaneda MM, Cappello P, Nguyen AV, Ralainirina N, Hardamon CR, Foubert P, Schmid MC, Sun P, Mose E, Bouvet M, Lowy AM, Valasek MA, Sasik R, Novelli F, Hirsch E, Varner JA. Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression. Cancer Discov 2016;6:870-85. [PMID: 27179037 DOI: 10.1158/2159-8290.CD-15-1346] [Cited by in Crossref: 134] [Cited by in F6Publishing: 153] [Article Influence: 22.3] [Reference Citation Analysis]
244 Whatcott CJ, Han H, Von Hoff DD. Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction. Cancer J. 2015;21:299-306. [PMID: 26222082 DOI: 10.1097/ppo.0000000000000140] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
245 Narayanan V, Weekes CD. Molecular therapeutics in pancreas cancer. World J Gastrointest Oncol 2016; 8(4): 366-379 [PMID: 27096032 DOI: 10.4251/wjgo.v8.i4.366] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
246 Romeo C, Weber MC, Zarei M, DeCicco D, Chand SN, Lobo AD, Winter JM, Sawicki JA, Sachs JN, Meisner-Kober N, Yeo CJ, Vadigepalli R, Tykocinski ML, Brody JR. HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells. Mol Cancer Res 2016;14:599-611. [PMID: 27053682 DOI: 10.1158/1541-7786.MCR-15-0448] [Cited by in Crossref: 27] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis]
247 Indolfi L, Ligorio M, Ting DT, Xega K, Tzafriri AR, Bersani F, Aceto N, Thapar V, Fuchs BC, Deshpande V, Baker AB, Ferrone CR, Haber DA, Langer R, Clark JW, Edelman ER. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Biomaterials 2016;93:71-82. [PMID: 27082874 DOI: 10.1016/j.biomaterials.2016.03.044] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
248 Ko AH. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan. Int J Nanomedicine 2016;11:1225-35. [PMID: 27099488 DOI: 10.2147/IJN.S88084] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
249 Abrams MJ, Rakszawski K, Vasekar M, Passero F, Abbas A, Jia Y, Saif MW. Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology. Therap Adv Gastroenterol 2016;9:141-51. [PMID: 26929776 DOI: 10.1177/1756283X15622601] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
250 Duluc C, Moatassim-Billah S, Chalabi-Dchar M, Perraud A, Samain R, Breibach F, Gayral M, Cordelier P, Delisle MB, Bousquet-Dubouch MP. Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol Med. 2015;7:735-753. [PMID: 25834145 DOI: 10.15252/emmm.201404346] [Cited by in Crossref: 107] [Cited by in F6Publishing: 124] [Article Influence: 17.8] [Reference Citation Analysis]
251 Ahn DH, Ko AH, Meropol NJ, Bekaii-Saab TS. Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. Am Soc Clin Oncol Educ Book 2015;:e222-7. [PMID: 25993177 DOI: 10.14694/EdBook_AM.2015.35.e222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
252 Kao SC, Kirschner MB, Cooper WA, Tran T, Burgers S, Wright C, Korse T, van den Broek D, Edelman J, Vallely M, McCaughan B, Pavlakis N, Clarke S, Molloy MP, van Zandwijk N, Reid G. A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. Br J Cancer 2016;114:524-31. [PMID: 26889976 DOI: 10.1038/bjc.2015.470] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
253 Viterbo D, Gausman V, Gonda T. Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy. World J Gastrointest Endosc 2016; 8(3): 128-142 [PMID: 26862363 DOI: 10.4253/wjge.v8.i3.128] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
254 Cho SY, Kang W, Han JY, Min S, Kang J, Lee A, Kwon JY, Lee C, Park H. An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts. Mol Cells 2016;39:77-86. [PMID: 26831452 DOI: 10.14348/molcells.2016.2350] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 11.3] [Reference Citation Analysis]
255 Kim H, Samuel S, Lopez-Casas P, Grizzle W, Hidalgo M, Kovar J, Oelschlager D, Zinn K, Warram J, Buchsbaum D. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Mol Cancer Ther. 2016;15:680-688. [PMID: 26832793 DOI: 10.1158/1535-7163.mct-15-0764] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
256 Chand S, O'Hayer K, Blanco FF, Winter JM, Brody JR. The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms. Int J Biol Sci 2016;12:273-82. [PMID: 26929734 DOI: 10.7150/ijbs.14951] [Cited by in Crossref: 57] [Cited by in F6Publishing: 67] [Article Influence: 9.5] [Reference Citation Analysis]
257 Ramanathan RK, Goldstein D, Korn RL, Arena F, Moore M, Siena S, Teixeira L, Tabernero J, Van Laethem JL, Liu H. Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. Ann Oncol. 2016;27:648-653. [PMID: 26802153 DOI: 10.1093/annonc/mdw020] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
258 Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A. CA19-9 decrease at 8 wk as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol. 2016;27:654-660. [PMID: 26802160 DOI: 10.1093/annonc/mdw006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 60] [Article Influence: 8.0] [Reference Citation Analysis]
259 Guo LN, Gao HY, He M, Liu D. Significance of expression of mannose receptor in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2016; 24(1): 37-43 [DOI: 10.11569/wcjd.v24.i1.37] [Reference Citation Analysis]
260 Han W, Cao F, Chen MB, Lu RZ, Wang HB, Yu M, Shi CT, Ding HZ. Prognostic Value of SPARC in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. PLoS One. 2016;11:e0145803. [PMID: 26731428 DOI: 10.1371/journal.pone.0145803] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
261 Tewari M. Pancreatic Cancer: a Challenge to Cure. Indian J Surg 2015;77:350-7. [PMID: 26722196 DOI: 10.1007/s12262-015-1369-6] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
262 Sun JD, Liu Q, Ahluwalia D, Li W, Meng F, Wang Y, Bhupathi D, Ruprell AS, Hart CP. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. Cancer Biol Ther. 2015;16:438-449. [PMID: 25679067 DOI: 10.1080/15384047.2014.1003005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
263 Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestani S, Liudahl SM, Truitt M, Olson P, Kim G, Hanahan D, Tempero MA, Sheppard B, Irving B, Chang BY, Varner JA, Coussens LM. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discov 2016;6:270-85. [PMID: 26715645 DOI: 10.1158/2159-8290.CD-15-0827] [Cited by in Crossref: 259] [Cited by in F6Publishing: 275] [Article Influence: 37.0] [Reference Citation Analysis]
264 Mao YH, Yu CZ. Current situation and predicament of multidisciplinary treatment of pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2015; 23(36): 5750-5759 [DOI: 10.11569/wcjd.v23.i36.5750] [Reference Citation Analysis]
265 Dhayat SA, Abdeen B, Köhler G, Senninger N, Haier J, Mardin WA. MicroRNA-100 and microRNA-21 as markers of survival and chemotherapy response in pancreatic ductal adenocarcinoma UICC stage II. Clin Epigenetics 2015;7:132. [PMID: 26705427 DOI: 10.1186/s13148-015-0166-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
266 Millis SZ, Ejadi S, Demeure MJ. Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy. Biomark Cancer 2015;7:69-76. [PMID: 26715866 DOI: 10.4137/BIC.S34292] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
267 Keenan MM, Chi JT. Alternative fuels for cancer cells. Cancer J. 2015;21:49-55. [PMID: 25815843 DOI: 10.1097/ppo.0000000000000104] [Cited by in Crossref: 60] [Cited by in F6Publishing: 32] [Article Influence: 8.6] [Reference Citation Analysis]
268 Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials 2015;16:575. [PMID: 26673577 DOI: 10.1186/s13063-015-1101-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
269 Schmuck RB, de Carvalho-Fischer CV, Neumann C, Pratschke J, Bahra M. Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity. Cancer Med. 2016;5:88-99. [PMID: 26645826 DOI: 10.1002/cam4.566] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
270 Yu X, Jin C. Application of albumin-based nanoparticles in the management of cancer. J Mater Sci Mater Med 2016;27:4. [PMID: 26610927 DOI: 10.1007/s10856-015-5618-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
271 Ahn DH, Williams TM, Goldstein DA, El-Rayes B, Bekaii-Saab T. Adjuvant therapy for pancreas cancer in an era of value based cancer care. Cancer Treat Rev 2016;42:10-7. [PMID: 26620819 DOI: 10.1016/j.ctrv.2015.11.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
272 Xie T, Musteanu M, Lopez-Casas PP, Shields DJ, Olson P, Rejto PA, Hidalgo M. Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor Progression. PLoS One 2015;10:e0142631. [PMID: 26555578 DOI: 10.1371/journal.pone.0142631] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
273 Yu X, Di Y, Xie C, Song Y, He H, Li H, Pu X, Lu W, Fu D, Jin C. An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line. Int J Nanomedicine 2015;10:6825-34. [PMID: 26586944 DOI: 10.2147/IJN.S93835] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
274 Delitto D, Black BS, Sorenson HL, Knowlton AE, Thomas RM, Sarosi GA, Moldawer LL, Behrns KE, Liu C, George TJ. The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival. BMC Cancer. 2015;15:783. [PMID: 26498838 DOI: 10.1186/s12885-015-1820-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
275 Amedei A, Niccolai E, Prisco D. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Hum Vaccin Immunother. 2014;10:3354-3368. [PMID: 25483688 DOI: 10.4161/hv.34392] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
276 Takai E, Yachida S. Genomic alterations in pancreatic cancer and their relevance to therapy. World J Gastrointest Oncol 2015; 7(10): 250-258 [PMID: 26483879 DOI: 10.4251/wjgo.v7.i10.250] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
277 Palam LR, Gore J, Craven KE, Wilson JL, Korc M. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma. Cell Death Dis 2015;6:e1913. [PMID: 26469962 DOI: 10.1038/cddis.2015.264] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 9.0] [Reference Citation Analysis]
278 Korkeila EA. Advanced pancreatic cancer - how to choose an adequate treatment option. World J Gastroenterol 2015; 21(38): 10709-10713 [PMID: 26478662 DOI: 10.3748/wjg.v21.i38.10709] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
279 Bachet JB, Chibaudel B, Bonnetain F, Validire P, Hammel P, André T, Louvet C; GERCOR group. A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial. BMC Cancer 2015;15:653. [PMID: 26445094 DOI: 10.1186/s12885-015-1656-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
280 Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Conry R, Haydon A, Robert C, Ernst S, Homsi J, Grob JJ, Kendra K, Agarwala SS, Li M, Clawson A, Brachmann C, Karnoub M, Elias I, Renschler MF, Hauschild A. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. Ann Oncol 2015;26:2267-74. [PMID: 26410620 DOI: 10.1093/annonc/mdv324] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
281 Hoffman RM, Bouvet M. Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer. Expert Opin Pharmacother 2015;16:943-7. [PMID: 25887245 DOI: 10.1517/14656566.2015.1016912] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
282 Maréchal R, Puleo F, Demols A, Verset G, Laethem JV. Personalized medicine in pancreatic cancer: the revolution has begun. Per Med 2015;12:515-23. [PMID: 29749894 DOI: 10.2217/pme.15.15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
283 Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol 2015; 21(31): 9297-9316 [PMID: 26309356 DOI: 10.3748/wjg.v21.i31.9297] [Cited by in CrossRef: 91] [Cited by in F6Publishing: 82] [Article Influence: 13.0] [Reference Citation Analysis]
284 Usón Junior PL, França MS, Rodrigues HV, Macedo AL, Goldenberg A, Smaletz O, Armentano DP, Simon SD, Gansl RC. Higher overall survival in metastatic pancreatic cancer: the impact of where and how treatment is delivered. Einstein (Sao Paulo) 2015;13:347-51. [PMID: 26313433 DOI: 10.1590/S1679-45082015AO3303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
285 Fathi A, Christians KK, George B, Ritch PS, Erickson BA, Tolat P, Johnston FM, Evans DB, Tsai S. Neoadjuvant therapy for localized pancreatic cancer: guiding principles. J Gastrointest Oncol. 2015;6:418-429. [PMID: 26261728 DOI: 10.3978/j.issn.2078-6891.2015.053] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
286 Kundranda MN, Niu J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des Devel Ther 2015;9:3767-77. [PMID: 26244011 DOI: 10.2147/DDDT.S88023] [Cited by in Crossref: 93] [Cited by in F6Publishing: 46] [Article Influence: 13.3] [Reference Citation Analysis]
287 Kamphorst JJ, Nofal M, Commisso C, Hackett SR, Lu W, Grabocka E, Vander Heiden MG, Miller G, Drebin JA, Bar-Sagi D, Thompson CB, Rabinowitz JD. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res 2015;75:544-53. [PMID: 25644265 DOI: 10.1158/0008-5472.CAN-14-2211] [Cited by in Crossref: 400] [Cited by in F6Publishing: 416] [Article Influence: 57.1] [Reference Citation Analysis]
288 Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer. 2015;15:311-316. [PMID: 25907221 DOI: 10.1038/nrc3944] [Cited by in Crossref: 217] [Cited by in F6Publishing: 212] [Article Influence: 31.0] [Reference Citation Analysis]
289 Chiorean EG, Coveler AL. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther. 2015;9:3529-3545. [PMID: 26185420 DOI: 10.2147/DDDT.S60328] [Cited by in Crossref: 74] [Cited by in F6Publishing: 48] [Article Influence: 10.6] [Reference Citation Analysis]
290 Min Y, Caster JM, Eblan MJ, Wang AZ. Clinical Translation of Nanomedicine. Chem Rev 2015;115:11147-90. [PMID: 26088284 DOI: 10.1021/acs.chemrev.5b00116] [Cited by in Crossref: 424] [Cited by in F6Publishing: 377] [Article Influence: 60.6] [Reference Citation Analysis]
291 Thillai K, Sarker D, Ross P. Progress in pancreatic cancer therapeutics: The potential to exploit molecular targets. World J Pharmacol 2015; 4(2): 180-192 [DOI: 10.5497/wjp.v4.i2.180] [Reference Citation Analysis]
292 Chang J, Schomer D, Dragovich T. Anatomical, Physiological, and Molecular Imaging for Pancreatic Cancer: Current Clinical Use and Future Implications. Biomed Res Int 2015;2015:269641. [PMID: 26146615 DOI: 10.1155/2015/269641] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
293 Xie D, Xie K. Pancreatic cancer stromal biology and therapy. Genes Dis. 2015;2:133-143. [PMID: 26114155 DOI: 10.1016/j.gendis.2015.01.002] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 10.9] [Reference Citation Analysis]
294 Seicean A, Petrusel L, Seicean R. New targeted therapies in pancreatic cancer. World J Gastroenterol 2015; 21(20): 6127-6145 [PMID: 26034349 DOI: 10.3748/wjg.v21.i20.6127] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
295 Bertino EM, Williams TM, Nana-Sinkam SP, Shilo K, Chatterjee M, Mo X, Rahmani M, Phillips GS, Villalona-Calero MA, Otterson GA. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients. Clin Lung Cancer 2015;16:466-74. [PMID: 26123189 DOI: 10.1016/j.cllc.2015.05.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
296 Goel G, Sun W. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol. 2015;8:44. [PMID: 25935754 DOI: 10.1186/s13045-015-0141-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
297 Vaccaro V, Sperduti I, Vari S, Bria E, Melisi D, Garufi C, Nuzzo C, Scarpa A, Tortora G, Cognetti F, Reni M, Milella M. Metastatic pancreatic cancer: Is there a light at the end of the tunnel? World J Gastroenterol 2015; 21(16): 4788-4801 [PMID: 25944992 DOI: 10.3748/wjg.v21.i16.4788] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 48] [Article Influence: 7.1] [Reference Citation Analysis]
298 Azaro A, Rodon J, Calles A, Braña I, Hidalgo M, Lopez-Casas PP, Munoz M, Westwood P, Miller J, Moser BA, Ohnmacht U, Bumgardner W, Benhadji KA, Calvo E. A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs 2015;33:710-9. [PMID: 25902900 DOI: 10.1007/s10637-015-0241-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
299 Frank TS, Sun X, Zhang Y, Yang J, Fisher WE, Gingras MC, Li M. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer. Cancer Lett 2015;363:1-6. [PMID: 25890222 DOI: 10.1016/j.canlet.2015.04.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
300 Buchholz M, Honstein T, Kirchhoff S, Kreider R, Schmidt H, Sipos B, Gress TM. A multistep high-content screening approach to identify novel functionally relevant target genes in pancreatic cancer. PLoS One 2015;10:e0122946. [PMID: 25849100 DOI: 10.1371/journal.pone.0122946] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
301 Meng H, Wang M, Liu H, Liu X, Situ A, Wu B, Ji Z, Chang CH, Nel AE. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS Nano 2015;9:3540-57. [PMID: 25776964 DOI: 10.1021/acsnano.5b00510] [Cited by in Crossref: 279] [Cited by in F6Publishing: 259] [Article Influence: 39.9] [Reference Citation Analysis]
302 Nishiwada S, Sho M, Yasuda S, Shimada K, Yamato I, Akahori T, Kinoshita S, Nagai M, Konishi N, Nakajima Y. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. J Exp Clin Cancer Res 2015;34:30. [PMID: 25888293 DOI: 10.1186/s13046-015-0144-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 56] [Article Influence: 5.9] [Reference Citation Analysis]
303 Perkhofer L, Ettrich TJ, Seufferlein T. Pancreatic Cancer: Progress in Systemic Therapy. Gastrointest Tumors 2014;1:167-79. [PMID: 26672477 DOI: 10.1159/000380785] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
304 Kim EJ, Semrad TJ, Bold RJ. Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Expert Opin Investig Drugs. 2015;24:781-794. [PMID: 25809274 DOI: 10.1517/13543784.2015.1026963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
305 Ernsting MJ, Hoang B, Lohse I, Undzys E, Cao P, Do T, Gill B, Pintilie M, Hedley D, Li SD. Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle. J Control Release. 2015;206:122-130. [PMID: 25804872 DOI: 10.1016/j.jconrel.2015.03.023] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 9.6] [Reference Citation Analysis]
306 Ansari D, Gustafsson A, Andersson R. Update on the management of pancreatic cancer: Surgery is not enough. World J Gastroenterol 2015; 21(11): 3157-3165 [PMID: 25805920 DOI: 10.3748/wjg.v21.i11.3157] [Cited by in CrossRef: 97] [Cited by in F6Publishing: 91] [Article Influence: 13.9] [Reference Citation Analysis]
307 Gharaibeh M, McBride A, Bootman JL, Abraham I. Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer. Br J Cancer. 2015;112:1301-1305. [PMID: 25791875 DOI: 10.1038/bjc.2015.65] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
308 Teague A, Lim KH, Wang-Gillam A. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther Adv Med Oncol 2015;7:68-84. [PMID: 25755680 DOI: 10.1177/1758834014564775] [Cited by in Crossref: 86] [Cited by in F6Publishing: 91] [Article Influence: 12.3] [Reference Citation Analysis]
309 Wei D, Zhang Q, Schreiber JS, Parsels LA, Abulwerdi FA, Kausar T, Lawrence TS, Sun Y, Nikolovska-Coleska Z, Morgan MA. Targeting mcl-1 for radiosensitization of pancreatic cancers. Transl Oncol 2015;8:47-54. [PMID: 25749177 DOI: 10.1016/j.tranon.2014.12.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
310 Cheng HB, Bo Y, Shen WX, Ren XG, Tan JN, Jia ZR, Xu CL. Longikaurin E induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS. Naunyn Schmiedebergs Arch Pharmacol 2015;388:623-34. [PMID: 25743573 DOI: 10.1007/s00210-015-1107-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
311 Puleo F, Maréchal R, Demetter P, Bali MA, Calomme A, Closset J, Bachet JB, Deviere J, Laethem JLV. New challenges in perioperative management of pancreatic cancer. World J Gastroenterol 2015; 21(8): 2281-2293 [PMID: 25741134 DOI: 10.3748/wjg.v21.i8.2281] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
312 Whatcott CJ, Diep CH, Jiang P, Watanabe A, LoBello J, Sima C, Hostetter G, Shepard HM, Von Hoff DD, Han H. Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer. Clin Cancer Res. 2015;21:3561-3568. [PMID: 25695692 DOI: 10.1158/1078-0432.ccr-14-1051] [Cited by in Crossref: 244] [Cited by in F6Publishing: 308] [Article Influence: 34.9] [Reference Citation Analysis]
313 Chien W, Sun QY, Lee KL, Ding LW, Wuensche P, Torres-Fernandez LA, Tan SZ, Tokatly I, Zaiden N, Poellinger L, Mori S, Yang H, Tyner JW, Koeffler HP. Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. Mol Oncol 2015;9:889-905. [PMID: 25637283 DOI: 10.1016/j.molonc.2015.01.002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
314 Sirohi B, Singh A, Dawood S, Shrikhande SV. Advances in chemotherapy for pancreatic cancer. Indian J Surg Oncol 2015;6:47-56. [PMID: 25937764 DOI: 10.1007/s13193-014-0371-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
315 Tabernero J, Chiorean EG, Infante JR, Hingorani SR, Ganju V, Weekes C, Scheithauer W, Ramanathan RK, Goldstein D, Penenberg DN, Romano A, Ferrara S, Von Hoff DD. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist. 2015;20:143-150. [PMID: 25582141 DOI: 10.1634/theoncologist.2014-0394] [Cited by in Crossref: 79] [Cited by in F6Publishing: 89] [Article Influence: 11.3] [Reference Citation Analysis]
316 Valsecchi ME, Díaz-Cantón E, de la Vega M, Littman SJ. Recent treatment advances and novel therapies in pancreas cancer: a review. J Gastrointest Cancer 2014;45:190-201. [PMID: 24343588 DOI: 10.1007/s12029-013-9561-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
317 Mian OY, Ram AN, Tuli R, Herman JM. Management options in locally advanced pancreatic cancer. Curr Oncol Rep 2014;16:388. [PMID: 24740136 DOI: 10.1007/s11912-014-0388-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
318 Wang XY, Yang F, Jin C, Fu DL. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer. World J Gastroenterol 2014; 20(42): 15580-15589 [PMID: 25400441 DOI: 10.3748/wjg.v20.i42.15580] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
319 Kaleağasıoğlu F, Berger MR. SIBLINGs and SPARC families: Their emerging roles in pancreatic cancer. World J Gastroenterol 2014; 20(40): 14747-14759 [PMID: 25356037 DOI: 10.3748/wjg.v20.i40.14747] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
320 Kadera BE, Toste PA, Wu N, Li L, Nguyen AH, Dawson DW, Donahue TR. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition. Clin Cancer Res. 2015;21:157-165. [PMID: 25348515 DOI: 10.1158/1078-0432.ccr-14-0610] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
321 Schober M, Jesenofsky R, Faissner R, Weidenauer C, Hagmann W, Michl P, Heuchel RL, Haas SL, Löhr JM. Desmoplasia and chemoresistance in pancreatic cancer. Cancers (Basel) 2014;6:2137-54. [PMID: 25337831 DOI: 10.3390/cancers6042137] [Cited by in Crossref: 72] [Cited by in F6Publishing: 81] [Article Influence: 9.0] [Reference Citation Analysis]
322 Sinn M, Denkert C, Striefler JK, Pelzer U, Stieler JM, Bahra M, Lohneis P, Dörken B, Oettle H, Riess H. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Br J Cancer. 2014;111:1917-1923. [PMID: 25314063 DOI: 10.1038/bjc.2014.495] [Cited by in Crossref: 74] [Cited by in F6Publishing: 87] [Article Influence: 9.3] [Reference Citation Analysis]
323 Socinski MA. Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer. Curr Oncol 2014;21:e691-703. [PMID: 25302040 DOI: 10.3747/co.21.1997] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
324 Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014;211:1503-1523. [PMID: 25071162 DOI: 10.1084/jem.20140692] [Cited by in Crossref: 423] [Cited by in F6Publishing: 469] [Article Influence: 52.9] [Reference Citation Analysis]
325 Kunzmann V, Herrmann K, Bluemel C, Kapp M, Hartlapp I, Steger U. Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer. Case Rep Oncol 2014;7:648-55. [PMID: 25408659 DOI: 10.1159/000367966] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
326 Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 2014; 20(32): 11142-11159 [PMID: 25170201 DOI: 10.3748/wjg.v20.i32.11142] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 70] [Article Influence: 10.3] [Reference Citation Analysis]
327 Ormanns S, Siveke JT, Heinemann V, Haas M, Sipos B, Schlitter AM, Esposito I, Jung A, Laubender RP, Kruger S, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR, Gauler TC, Märten A, Geissler M, Greten TF, Kirchner T, Boeck S. pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. BMC Cancer 2014;14:624. [PMID: 25164437 DOI: 10.1186/1471-2407-14-624] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
328 Xu Z, Pothula SP, Wilson JS, Apte MV. Pancreatic cancer and its stroma: A conspiracy theory. World J Gastroenterol 2014; 20(32): 11216-11229 [PMID: 25170206 DOI: 10.3748/wjg.v20.i32.11216] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 86] [Article Influence: 11.5] [Reference Citation Analysis]
329 Kruger S, Haas M, Ormanns S, Bächmann S, Siveke JT, Kirchner T, Heinemann V, Boeck S. Translational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts. World J Gastroenterol 2014; 20(31): 10769-10777 [PMID: 25152580 DOI: 10.3748/wjg.v20.i31.10769] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
330 Timmerman RD, Herman J, Cho LC. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol 2014;32:2847-54. [PMID: 25113761 DOI: 10.1200/JCO.2014.55.4675] [Cited by in Crossref: 123] [Cited by in F6Publishing: 128] [Article Influence: 15.4] [Reference Citation Analysis]
331 Zhang R, Yang J, Sima M, Zhou Y, Kopeček J. Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates. Proc Natl Acad Sci U S A 2014;111:12181-6. [PMID: 25092316 DOI: 10.1073/pnas.1406233111] [Cited by in Crossref: 95] [Cited by in F6Publishing: 100] [Article Influence: 11.9] [Reference Citation Analysis]
332 Arslan C, Yalcin S. Current and future systemic treatment options in metastatic pancreatic cancer. J Gastrointest Oncol. 2014;5:280-295. [PMID: 25083302 DOI: 10.3978/j.issn.2078-6891.2014.030] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
333 Lamarca A, Feliu J. Pancreatic biomarkers: Could they be the answer? World J Gastroenterol 2014; 20(24): 7819-7829 [PMID: 24976720 DOI: 10.3748/wjg.v20.i24.7819] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
334 Sjoquist KM, Chin VT, Chantrill LA, O’Connor C, Hemmings C, Chang DK, Chou A, Pajic M, Johns AL, Nagrial AM, Biankin AV, Yip D. Personalising pancreas cancer treatment: When tissue is the issue. World J Gastroenterol 2014; 20(24): 7849-7863 [PMID: 24976722 DOI: 10.3748/wjg.v20.i24.7849] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
335 Dragovich T, Laheru D, Dayyani F, Bolejack V, Smith L, Seng J, Burris H, Rosen P, Hidalgo M, Ritch P. Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol. 2014;74:379-387. [PMID: 24939212 DOI: 10.1007/s00280-014-2499-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
336 Hollevoet K, Mason-Osann E, Liu XF, Imhof-Jung S, Niederfellner G, Pastan I. In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer. Mol Cancer Ther 2014;13:2040-9. [PMID: 24928849 DOI: 10.1158/1535-7163.MCT-14-0089-T] [Cited by in Crossref: 65] [Cited by in F6Publishing: 74] [Article Influence: 8.1] [Reference Citation Analysis]
337 Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, Ellenrieder V, Jodrell DI, Tuveson DA. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut 2014;63:974-83. [PMID: 24067278 DOI: 10.1136/gutjnl-2013-305559] [Cited by in Crossref: 103] [Cited by in F6Publishing: 130] [Article Influence: 12.9] [Reference Citation Analysis]
338 Guo S, Lin CM, Xu Z, Miao L, Wang Y, Huang L. Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano 2014;8:4996-5009. [PMID: 24720540 DOI: 10.1021/nn5010815] [Cited by in Crossref: 128] [Cited by in F6Publishing: 122] [Article Influence: 16.0] [Reference Citation Analysis]
339 Cabrera MC, Tilahun E, Nakles R, Diaz-Cruz ES, Charabaty A, Suy S, Jackson P, Ley L, Slack R, Jha R. Human Pancreatic Cancer-Associated Stellate Cells Remain Activated after in vivo Chemoradiation. Front Oncol. 2014;4:102. [PMID: 24847445 DOI: 10.3389/fonc.2014.00102] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
340 Waghray M, Yalamanchili M, di Magliano MP, Simeone DM. Deciphering the role of stroma in pancreatic cancer. Curr Opin Gastroenterol. 2013;29:537-543. [PMID: 23892539 DOI: 10.1097/mog.0b013e328363affe] [Cited by in Crossref: 76] [Cited by in F6Publishing: 61] [Article Influence: 9.5] [Reference Citation Analysis]
341 McCarroll JA, Naim S, Sharbeen G, Russia N, Lee J, Kavallaris M, Goldstein D, Phillips PA. Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. Front Physiol 2014;5:141. [PMID: 24782785 DOI: 10.3389/fphys.2014.00141] [Cited by in Crossref: 61] [Cited by in F6Publishing: 76] [Article Influence: 7.6] [Reference Citation Analysis]
342 Drifka CR, Eliceiri KW, Weber SM, Kao WJ. A bioengineered heterotypic stroma-cancer microenvironment model to study pancreatic ductal adenocarcinoma. Lab Chip 2013;13:3965-75. [PMID: 23959166 DOI: 10.1039/c3lc50487e] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
343 Smith LA, Jamieson NB, McKay CJ. Investigation and management of pancreatic tumours. Frontline Gastroenterol 2014;5:144-52. [PMID: 28839761 DOI: 10.1136/flgastro-2013-100364] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
344 Herman JM. Pancreaticobiliary malignancies: past, present, and future. Semin Radiat Oncol 2014;24:61-6. [PMID: 24635862 DOI: 10.1016/j.semradonc.2013.11.009] [Reference Citation Analysis]
345 Zhu C, Zhou GX. Inhibition of arachidonic acid metabolism to decrease pancreatic cancer cell proliferation. Shijie Huaren Xiaohua Zazhi 2014; 22(8): 1106-1111 [DOI: 10.11569/wcjd.v22.i8.1106] [Reference Citation Analysis]
346 Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M. Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'. Br J Cancer 2014;111:1677-8. [PMID: 24642623 DOI: 10.1038/bjc.2014.129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
347 Ramírez N, Viúdez A, Hernández-García I, Guerrero D, Gómez-Dorronsoro M, Herrera FJ, Vila J, Beloki L, Ciaúrriz M, Mansilla C, Vera R. Stellate cells, a point of light in the dark night of pancreatic cancer. Br J Cancer 2014;111:1676-7. [PMID: 24642614 DOI: 10.1038/bjc.2014.59] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
348 Chen YW, Hsiao PJ, Weng CC, Kuo KK, Kuo TL, Wu DC, Hung WC, Cheng KH. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells. BMC Cancer. 2014;14:181. [PMID: 24625091 DOI: 10.1186/1471-2407-14-181] [Cited by in Crossref: 29] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
349 Olowokure O, Qi X. Pancreatic cancer: current standards, working towards a new therapeutic approach. Expert Rev Anticancer Ther 2014;14:495-7. [PMID: 24621210 DOI: 10.1586/14737140.2014.895937] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
350 McAllister F, Pineda DM, Jimbo M, Lal S, Burkhart RA, Moughan J, Winter KA, Abdelmohsen K, Gorospe M, Acosta Ade J, Lankapalli RH, Winter JM, Yeo CJ, Witkiewicz AK, Iacobuzio-Donahue CA, Laheru D, Brody JR. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial. Cancer Biol Ther 2014;15:688-98. [PMID: 24618665 DOI: 10.4161/cbt.28413] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
351 Ghosn M, Kourie HR, Karak FE, Hanna C, Antoun J, Nasr D. Optimum chemotherapy in the management of metastatic pancreatic cancer. World J Gastroenterol 2014; 20(9): 2352-2357 [PMID: 24605032 DOI: 10.3748/wjg.v20.i9.2352] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
352 Awasthi N, Zhang C, Schwarz AM, Hinz S, Schwarz MA, Schwarz RE. Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer. Mol Cancer Ther 2014;13:1032-43. [PMID: 24608575 DOI: 10.1158/1535-7163.MCT-13-0361] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
353 Louzoun Y, Xue C, Lesinski GB, Friedman A. A mathematical model for pancreatic cancer growth and treatments. J Theor Biol 2014;351:74-82. [PMID: 24594371 DOI: 10.1016/j.jtbi.2014.02.028] [Cited by in Crossref: 74] [Cited by in F6Publishing: 57] [Article Influence: 9.3] [Reference Citation Analysis]
354 Wilson JS, Pirola RC, Apte MV. Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression. Front Physiol. 2014;5:52. [PMID: 24592240 DOI: 10.3389/fphys.2014.00052] [Cited by in Crossref: 46] [Cited by in F6Publishing: 56] [Article Influence: 5.8] [Reference Citation Analysis]
355 Al-Hajeili M, Azmi AS, Choi M. Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. Onco Targets Ther 2014;7:187-92. [PMID: 24523592 DOI: 10.2147/OTT.S40705] [Cited by in Crossref: 4] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
356 Chan SL, Chan ST, Chan EH, He ZX. Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chin J Cancer 2014;33:267-76. [PMID: 24472302 DOI: 10.5732/cjc.013.10134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
357 McCarroll J, Teo J, Boyer C, Goldstein D, Kavallaris M, Phillips PA. Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. Front Physiol 2014;5:2. [PMID: 24478715 DOI: 10.3389/fphys.2014.00002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
358 Porter CE, Waddell JA, Solimando DA Jr. nab-Paclitaxel Plus Gemcitabine Regimen for Pancreatic Cancer. Hosp Pharm 2014;49:18-22. [PMID: 24421558 DOI: 10.1310/hpj4901-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
359 Liu F, Gore AJ, Wilson JL, Korc M. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine. PLoS One 2014;9:e84982. [PMID: 24409315 DOI: 10.1371/journal.pone.0084982] [Cited by in Crossref: 27] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
360 Neesse A, Krug S, Gress TM, Tuveson DA, Michl P. Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther. 2013;7:33-43. [PMID: 24379681 DOI: 10.2147/ott.s38111] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
361 Ueda JY, Athikomkulchai S, Miyatake R, Saiki I, Esumi H, Awale S. (+)-Grandifloracin, an antiausterity agent, induces autophagic PANC-1 pancreatic cancer cell death. Drug Des Devel Ther 2014;8:39-47. [PMID: 24379655 DOI: 10.2147/DDDT.S52168] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
362 Aguilera KY, Rivera LB, Hur H, Carbon JG, Toombs JE, Goldstein CD, Dellinger MT, Castrillon DH, Brekken RA. Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. Cancer Res 2014;74:1032-44. [PMID: 24346431 DOI: 10.1158/0008-5472.CAN-13-2800] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 6.4] [Reference Citation Analysis]
363 Halfdanarson TR, Haraldsdottir S, Borad MJ. Advances in systemic therapy for advanced pancreatobiliary malignancies. F1000Res 2013;2:105. [PMID: 24327864 DOI: 10.12688/f1000research.2-105.v1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
364 Ashman JB, Moss AA, Rule WG, Callister MG, Reddy KS, Mulligan DC, Collins JM, De Petris G, Gunderson LL, Borad M. Preoperative chemoradiation and IOERT for unresectable or borderline resectable pancreas cancer. J Gastrointest Oncol 2013;4:352-60. [PMID: 24294506 DOI: 10.3978/j.issn.2078-6891.2013.006] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
365 Peddi PF, Cho M, Wang J, Gao F, Wang-Gillam A. Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma. J Gastrointest Oncol. 2013;4:370-373. [PMID: 24294508 DOI: 10.3978/j.issn.2078-6891.2013.034] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
366 Meng H, Zhao Y, Dong J, Xue M, Lin YS, Ji Z, Mai WX, Zhang H, Chang CH, Brinker CJ, Zink JI, Nel AE. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. ACS Nano 2013;7:10048-65. [PMID: 24143858 DOI: 10.1021/nn404083m] [Cited by in Crossref: 126] [Cited by in F6Publishing: 118] [Article Influence: 14.0] [Reference Citation Analysis]
367 White E. Exploiting the bad eating habits of Ras-driven cancers. Genes Dev 2013;27:2065-71. [PMID: 24115766 DOI: 10.1101/gad.228122.113] [Cited by in Crossref: 110] [Cited by in F6Publishing: 107] [Article Influence: 12.2] [Reference Citation Analysis]
368 Pillai G, Ceballos-Coronel ML. Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists. SAGE Open Med 2013;1:2050312113513759. [PMID: 26770691 DOI: 10.1177/2050312113513759] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
369 Sipos B, Sperveslage J. [Will molecular diagnostics become established in pancreatic pathology?]. Pathologe 2013;34 Suppl 2:214-20. [PMID: 24196616 DOI: 10.1007/s00292-013-1865-z] [Reference Citation Analysis]
370 Hamada S, Masamune A, Shimosegawa T. Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer. Front Physiol 2013;4:331. [PMID: 24273517 DOI: 10.3389/fphys.2013.00331] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
371 Duffy AG, Greten TF. Immunological off-target effects of standard treatments in gastrointestinal cancers. Ann Oncol. 2014;25:24-32. [PMID: 24201974 DOI: 10.1093/annonc/mdt349] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
372 Olszewski AJ, Grossbard ML, Chung MS, Chalasani SB, Malamud S, Mirzoyev T, Kozuch PS. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. J Gastrointest Cancer 2013;44:182-9. [PMID: 23208490 DOI: 10.1007/s12029-012-9466-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
373 Malaney P, Nicosia SV, Davé V. One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett 2014;344:1-12. [PMID: 24157811 DOI: 10.1016/j.canlet.2013.10.010] [Cited by in Crossref: 184] [Cited by in F6Publishing: 174] [Article Influence: 20.4] [Reference Citation Analysis]
374 Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703. [PMID: 24131140 DOI: 10.1056/NEJMoa1304369] [Cited by in Crossref: 3143] [Cited by in F6Publishing: 3286] [Article Influence: 349.2] [Reference Citation Analysis]
375 Guo S, Huang L. Nanoparticles containing insoluble drug for cancer therapy. Biotechnol Adv 2014;32:778-88. [PMID: 24113214 DOI: 10.1016/j.biotechadv.2013.10.002] [Cited by in Crossref: 87] [Cited by in F6Publishing: 75] [Article Influence: 9.7] [Reference Citation Analysis]
376 Kumar R, Dholakia A, Rasheed Z. Stem cell-directed therapies in pancreatic cancer. Curr Probl Cancer 2013;37:280-6. [PMID: 24331183 DOI: 10.1016/j.currproblcancer.2013.10.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
377 Castellanos JA, Merchant NB. Intensity of follow-up after pancreatic cancer resection. Ann Surg Oncol 2014;21:747-51. [PMID: 24092447 DOI: 10.1245/s10434-013-3289-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
378 Stirland DL, Nichols JW, Miura S, Bae YH. Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J Control Release 2013;172:1045-64. [PMID: 24096014 DOI: 10.1016/j.jconrel.2013.09.026] [Cited by in Crossref: 151] [Cited by in F6Publishing: 139] [Article Influence: 16.8] [Reference Citation Analysis]
379 Cesca M, Bizzaro F, Zucchetti M, Giavazzi R. Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents. Front Oncol 2013;3:259. [PMID: 24102047 DOI: 10.3389/fonc.2013.00259] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 5.7] [Reference Citation Analysis]
380 Gnoni A, Licchetta A, Scarpa A, Azzariti A, Brunetti AE, Simone G, Nardulli P, Santini D, Aieta M, Delcuratolo S, Silvestris N. Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. Int J Mol Sci. 2013;14:19731-19762. [PMID: 24084722 DOI: 10.3390/ijms141019731] [Cited by in Crossref: 31] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
381 Ernsting MJ, Murakami M, Roy A, Li SD. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release 2013;172:782-94. [PMID: 24075927 DOI: 10.1016/j.jconrel.2013.09.013] [Cited by in Crossref: 566] [Cited by in F6Publishing: 579] [Article Influence: 62.9] [Reference Citation Analysis]
382 Zhang CΗ, Awasthi N, Schwarz MA, Schwarz RE. The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer. Int J Oncol 2013;43:1627-35. [PMID: 24042258 DOI: 10.3892/ijo.2013.2099] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
383 Faris JE, Wo JY. The controversial role of chemoradiation for patients with locally advanced pancreatic cancer. Oncologist 2013;18:981-5. [PMID: 24021761 DOI: 10.1634/theoncologist.2013-0270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
384 Mielgo A, Schmid MC. Impact of tumour associated macrophages in pancreatic cancer. BMB Rep 2013;46:131-8. [PMID: 23527856 DOI: 10.5483/bmbrep.2013.46.3.036] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 6.0] [Reference Citation Analysis]
385 Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, O'Dwyer PJ. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 2013;19:6286-6295. [PMID: 23983255 DOI: 10.1158/1078-0432.ccr-13-1320] [Cited by in Crossref: 272] [Cited by in F6Publishing: 282] [Article Influence: 30.2] [Reference Citation Analysis]
386 Kadera BE, Li L, Toste PA, Wu N, Adams C, Dawson DW, Donahue TR. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. PLoS One. 2013;8:e71978. [PMID: 23991015 DOI: 10.1371/journal.pone.0071978] [Cited by in Crossref: 99] [Cited by in F6Publishing: 109] [Article Influence: 11.0] [Reference Citation Analysis]
387 Westphalen CB, Olive KP. Genetically engineered mouse models of pancreatic cancer. Cancer J 2012;18:502-10. [PMID: 23187836 DOI: 10.1097/PPO.0b013e31827ab4c4] [Cited by in Crossref: 64] [Cited by in F6Publishing: 39] [Article Influence: 7.1] [Reference Citation Analysis]
388 Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, Korn WM. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Mol Cancer Ther. 2013;12:2213-2225. [PMID: 23918833 DOI: 10.1158/1535-7163.mct-13-0104] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
389 Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer 2013;109:926-33. [PMID: 23907428 DOI: 10.1038/bjc.2013.415] [Cited by in Crossref: 174] [Cited by in F6Publishing: 213] [Article Influence: 19.3] [Reference Citation Analysis]
390 Toomey P, Childs C, Luberice K, Ross S, Rosemurgy A. Nontherapeutic Celiotomy Incidence is not Affected by Volume of Pancreaticoduodenectomy for Pancreatic Adenocarcinoma. The American Surgeon 2013;79:781-5. [DOI: 10.1177/000313481307900818] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
391 Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.3322/caac.21190] [Cited by in Crossref: 479] [Cited by in F6Publishing: 538] [Article Influence: 53.2] [Reference Citation Analysis]
392 Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.1002/caac.21190] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
393 Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6:321-337. [PMID: 23814611 DOI: 10.1177/1756283x13478680] [Cited by in Crossref: 155] [Cited by in F6Publishing: 168] [Article Influence: 17.2] [Reference Citation Analysis]
394 Apte MV, Wilson JS, Lugea A, Pandol SJ. A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology. 2013;144:1210-1219. [PMID: 23622130 DOI: 10.1053/j.gastro.2012.11.037] [Cited by in Crossref: 249] [Cited by in F6Publishing: 276] [Article Influence: 27.7] [Reference Citation Analysis]
395 Wei D, Parsels LA, Karnak D, Davis MA, Parsels JD, Marsh AC, Zhao L, Maybaum J, Lawrence TS, Sun Y. Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair. Clin Cancer Res. 2013;19:4422-4432. [PMID: 23780887 DOI: 10.1158/1078-0432.ccr-13-0788] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 7.0] [Reference Citation Analysis]
396 Hermann PC, Trabulo SM, Sainz B Jr, Balic A, Garcia E, Hahn SA, Vandana M, Sahoo SK, Tunici P, Bakker A. Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. PLoS One. 2013;8:e66371. [PMID: 23825539 DOI: 10.1371/journal.pone.0066371] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
397 Olowokure O, Torregroza-Sanchez MP, Bedoya-Apraez ID. Gemcitabine plus Nab-Paclitaxel with chemoradiation in locally advanced pancreatic cancer (LAPC). J Gastrointest Oncol. 2013;4:E16-E18. [PMID: 23730523 DOI: 10.3978/j.issn.2078-6891.2013.013] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
398 Shi Y, Qin R, Wang ZK, Dai GH. Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma. Onco Targets Ther 2013;6:585-91. [PMID: 23737672 DOI: 10.2147/OTT.S44406] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
399 Cucinotto I, Fiorillo L, Gualtieri S, Arbitrio M, Ciliberto D, Staropoli N, Grimaldi A, Luce A, Tassone P, Caraglia M. Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? J Drug Deliv. 2013;2013:905091. [PMID: 23738077 DOI: 10.1155/2013/905091] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
400 Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Büchler MW. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol. 2013;10:323-333. [PMID: 23629472 DOI: 10.1038/nrclinonc.2013.66] [Cited by in Crossref: 133] [Cited by in F6Publishing: 132] [Article Influence: 14.8] [Reference Citation Analysis]
401 Azim HA Jr, Singhal S, Ignatiadis M, Desmedt C, Fumagalli D, Veys I, Larsimont D, Piccart M, Michiels S, Sotiriou C. Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis. PLoS One 2013;8:e62451. [PMID: 23638089 DOI: 10.1371/journal.pone.0062451] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
402 Makohon-Moore A, Brosnan JA, Iacobuzio-Donahue CA. Pancreatic cancer genomics: insights and opportunities for clinical translation. Genome Med 2013;5:26. [PMID: 23673020 DOI: 10.1186/gm430] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
403 Kadaba R, Birke H, Wang J, Hooper S, Andl CD, Di Maggio F, Soylu E, Ghallab M, Bor D, Froeling FE, Bhattacharya S, Rustgi AK, Sahai E, Chelala C, Sasieni P, Kocher HM. Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. J Pathol 2013;230:107-17. [PMID: 23359139 DOI: 10.1002/path.4172] [Cited by in Crossref: 83] [Cited by in F6Publishing: 117] [Article Influence: 9.2] [Reference Citation Analysis]
404 Zhang C, Awasthi N, Schwarz MA, Hinz S, Schwarz RE. Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer. PLoS One 2013;8:e58037. [PMID: 23460921 DOI: 10.1371/journal.pone.0058037] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
405 Wang XX, Yang M, Zhang YQ. Progress in understanding role of SPARC protein in gastric cancer. Shijie Huaren Xiaohua Zazhi 2013; 21(5): 409-414 [DOI: 10.11569/wcjd.v21.i5.409] [Reference Citation Analysis]
406 Vonderheide RH, Bayne LJ. Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr Opin Immunol 2013;25:200-5. [PMID: 23422836 DOI: 10.1016/j.coi.2013.01.006] [Cited by in Crossref: 112] [Cited by in F6Publishing: 108] [Article Influence: 12.4] [Reference Citation Analysis]
407 Guerra C, Barbacid M. Genetically engineered mouse models of pancreatic adenocarcinoma. Mol Oncol 2013;7:232-47. [PMID: 23506980 DOI: 10.1016/j.molonc.2013.02.002] [Cited by in Crossref: 102] [Cited by in F6Publishing: 100] [Article Influence: 11.3] [Reference Citation Analysis]
408 Steele CW, Jamieson NB, Evans TR, McKay CJ, Sansom OJ, Morton JP, Carter CR. Exploiting inflammation for therapeutic gain in pancreatic cancer. Br J Cancer. 2013;108:997-1003. [PMID: 23385734 DOI: 10.1038/bjc.2013.24] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 5.1] [Reference Citation Analysis]
409 Tsimberidou AM, Ye Y, Wheler J, Naing A, Hong D, Nwosu U, Hess KR, Wolff RA. A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. Cancer Chemother Pharmacol 2013;71:955-63. [PMID: 23377373 DOI: 10.1007/s00280-013-2088-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
410 Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18:4266-4276. [PMID: 22896693 DOI: 10.1158/1078-0432.ccr-11-3114] [Cited by in Crossref: 711] [Cited by in F6Publishing: 765] [Article Influence: 79.0] [Reference Citation Analysis]
411 Le A, Rajeshkumar NV, Maitra A, Dang CV. Conceptual framework for cutting the pancreatic cancer fuel supply. Clin Cancer Res. 2012;18:4285-4290. [PMID: 22896695 DOI: 10.1158/1078-0432.ccr-12-0041] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
412 Provenzano PP, Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br J Cancer. 2013;108:1-8. [PMID: 23299539 DOI: 10.1038/bjc.2012.569] [Cited by in Crossref: 173] [Cited by in F6Publishing: 192] [Article Influence: 19.2] [Reference Citation Analysis]
413 Yared JA, Tkaczuk KH. Update on taxane development: new analogs and new formulations. Drug Des Devel Ther 2012;6:371-84. [PMID: 23251087 DOI: 10.2147/DDDT.S28997] [Cited by in Crossref: 26] [Cited by in F6Publishing: 70] [Article Influence: 2.6] [Reference Citation Analysis]
414 Chiu J, Yau T. Metastatic pancreatic cancer: are we making progress in treatment. Gastroenterol Res Pract. 2012;2012:898931. [PMID: 23304129 DOI: 10.1155/2012/898931] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
415 Saif MW, Lee Y, Kim R. Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. Ther Adv Med Oncol 2012;4:341-6. [PMID: 23118809 DOI: 10.1177/1758834012453755] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
416 Navas C, Hernández-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell. 2012;22:318-330. [PMID: 22975375 DOI: 10.1016/j.ccr.2012.08.001] [Cited by in Crossref: 247] [Cited by in F6Publishing: 230] [Article Influence: 24.7] [Reference Citation Analysis]
417 Calvo F, Guillen Ponce C, Muñoz Beltran M, Sanjuanbenito Dehesa A. Multidisciplinary management of locally advanced–borderline resectable adenocarcinoma of the head of the pancreas. Clin Transl Oncol 2013;15:173-81. [DOI: 10.1007/s12094-012-0962-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
418 Boeck S, Jung A, Laubender RP, Neumann J, Egg R, Goritschan C, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Br J Cancer. 2013;108:469-476. [PMID: 23169292 DOI: 10.1038/bjc.2012.495] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
419 Gradishar WJ. Taxanes for the treatment of metastatic breast cancer. Breast Cancer (Auckl). 2012;6:159-171. [PMID: 23133315 DOI: 10.4137/bcbcr.s8205] [Cited by in Crossref: 19] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
420 Basu B, Jodrell D. Progress in pancreatic cancer: moving beyond gemcitabine? Expert Rev Anticancer Ther 2012;12:997-1000. [PMID: 23030218 DOI: 10.1586/era.12.78] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
421 Erkan M, Hausmann S, Michalski CW, Schlitter AM, Fingerle AA, Dobritz M, Friess H, Kleeff J. How fibrosis influences imaging and surgical decisions in pancreatic cancer. Front Physiol. 2012;3:389. [PMID: 23060813 DOI: 10.3389/fphys.2012.00389] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
422 Thacker CA, Weiss GJ, Tibes R, Blaydorn L, Downhour M, White E, Baldwin J, Hoff DD, Korn RL. 18-FDG PET/CT assessment of basal cell carcinoma with vismodegib. Cancer Med 2012;1:230-6. [PMID: 23342272 DOI: 10.1002/cam4.33] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
423 Tajima H, Ohta T, Shinbashi H, Hirose A, Tsukada T, Okamoto K, Nakanuma S, Sakai S, Furukawa H, Makino I, Nakamura K, Hayashi H, Oyama K, Inokuchi M, Nakagawara H, Miyashita T, Fujita H, Takamura H, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Mouri H, Ohtsubo K. Successful treatment of unresectable gallbladder cancer with low-dose paclitaxel as palliative chemotherapy after failure of gemcitabine and oral S-1: A case report. Oncol Lett 2012;4:1281-4. [PMID: 23226802 DOI: 10.3892/ol.2012.909] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
424 Belli C, Cereda S, Reni M. Role of taxanes in pancreatic cancer. World J Gastroenterol 2012; 18(33): 4457-4465 [PMID: 22969215 DOI: 10.3748/wjg.v18.i33.4457] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
425 Dimou A, Syrigos KN, Saif MW. Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer. Ther Adv Med Oncol 2012;4:271-9. [PMID: 22942909 DOI: 10.1177/1758834012446008] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 4.2] [Reference Citation Analysis]
426 Chang CM, Su YC, Lai NS, Huang KY, Chien SH, Chang YH, Lian WC, Hsu TW, Lee CC. The combined effect of individual and neighborhood socioeconomic status on cancer survival rates. PLoS One 2012;7:e44325. [PMID: 22957007 DOI: 10.1371/journal.pone.0044325] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 6.0] [Reference Citation Analysis]
427 Apte MV, Pirola RC, Wilson JS. Pancreatic stellate cells: a starring role in normal and diseased pancreas. Front Physiol 2012;3:344. [PMID: 22973234 DOI: 10.3389/fphys.2012.00344] [Cited by in Crossref: 151] [Cited by in F6Publishing: 187] [Article Influence: 15.1] [Reference Citation Analysis]
428 Van den Broeck A, Vankelecom H, Van Eijsden R, Govaere O, Topal B. Molecular markers associated with outcome and metastasis in human pancreatic cancer. J Exp Clin Cancer Res 2012;31:68. [PMID: 22925330 DOI: 10.1186/1756-9966-31-68] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 4.5] [Reference Citation Analysis]
429 Krell J, Frampton AE, Jiao LR, Stebbing J. Can pharmacogenomics guide effective anticancer therapy in pancreatic ductal adenocarcinoma? Pharmacogenomics 2012;13:977-9. [PMID: 22838942 DOI: 10.2217/pgs.12.73] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
430 Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, Zalupski MM, Bekaii-Saab T. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer. 2013;119:285-292. [PMID: 22786786 DOI: 10.1002/cncr.27734] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 7.0] [Reference Citation Analysis]
431 Kong X, Li L, Li Z, Xie K. Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications. Cytokine Growth Factor Rev 2012;23:343-56. [PMID: 22749856 DOI: 10.1016/j.cytogfr.2012.06.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
432 Costello E, Greenhalf W, Neoptolemos JP. New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol. 2012;9:435-444. [PMID: 22733351 DOI: 10.1038/nrgastro.2012.119] [Cited by in Crossref: 147] [Cited by in F6Publishing: 140] [Article Influence: 14.7] [Reference Citation Analysis]
433 Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, Friess H. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 2012;9:454-467. [PMID: 22710569 DOI: 10.1038/nrgastro.2012.115] [Cited by in Crossref: 401] [Cited by in F6Publishing: 384] [Article Influence: 40.1] [Reference Citation Analysis]
434 Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, Friess H. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol 2012;9:454-67. [PMID: 22710569 DOI: 10.1038/nrgastro.2012.115] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
435 Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418-429. [PMID: 22439937 DOI: 10.1016/j.ccr.2012.01.007] [Cited by in Crossref: 1156] [Cited by in F6Publishing: 1136] [Article Influence: 115.6] [Reference Citation Analysis]
436 Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, Lee D, Sung MW, Gulec SA, Goldsmith SJ, Manzone T, Holt M, O'Neil BH, Hall N, Montero AJ, Kauh J, Gold DV, Horne H, Wegener WA, Goldenberg DM. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer 2012;118:5497-506. [PMID: 22569804 DOI: 10.1002/cncr.27592] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 6.2] [Reference Citation Analysis]
437 Cukierman E, Bassi DE. The mesenchymal tumor microenvironment: a drug-resistant niche. Cell Adh Migr. 2012;6:285-296. [PMID: 22568991 DOI: 10.4161/cam.20210] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
438 Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A, Linden S. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Invest New Drugs. 2012;30:2391-2399. [PMID: 22547163 DOI: 10.1007/s10637-012-9818-6] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 7.7] [Reference Citation Analysis]
439 Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9:338-350. [PMID: 22508028 DOI: 10.1038/nrclinonc.2012.61] [Cited by in Crossref: 773] [Cited by in F6Publishing: 746] [Article Influence: 77.3] [Reference Citation Analysis]
440 Hung SW, Mody HR, Govindarajan R. Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett. 2012;320:138-149. [PMID: 22425961 DOI: 10.1016/j.canlet.2012.03.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
441 Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012;2:260-269. [PMID: 22585996 DOI: 10.1158/2159-8290.cd-11-0242] [Cited by in Crossref: 261] [Cited by in F6Publishing: 282] [Article Influence: 26.1] [Reference Citation Analysis]
442 Xie L, Kassner M, Munoz RM, Que QQ, Kiefer J, Zhao Y, Mousses S, Yin HH, Von Hoff DD, Han H. Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. Biochem Pharmacol 2012;83:452-61. [PMID: 22100984 DOI: 10.1016/j.bcp.2011.11.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
443 Hoge CW, Sethabutr O, Bodhidatta L, Echeverria P, Robertson DC, Morris JG Jr. Use of a synthetic oligonucleotide probe to detect strains of non-serovar O1 Vibrio cholerae carrying the gene for heat-stable enterotoxin (NAG-ST). J Clin Microbiol. 1990;28:1473-1476. [PMID: 2380369 DOI: 10.1093/carcin/bgt227] [Cited by in Crossref: 74] [Cited by in F6Publishing: 80] [Article Influence: 2.3] [Reference Citation Analysis]